aspirin has been researched along with Disease Exacerbation in 255 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 9.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined." | 9.24 | ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. ( Backman, V; Carolan, PJ; Chan, AT; Chin, SM; Chung, DC; Colizzo, FP; Drew, DA; Flagg, M; Freedman, M; Gala, M; Garber, JJ; Gilpin, KK; Huttenhower, C; Kedrin, D; Khalili, H; Kwon, DS; Markowitz, SD; Milne, GL; Nishioka, NS; Parziale, M; Pond, E; Rawlings, CA; Richter, JM; Roy, HK; Schuck, MM; Staller, K; Stewart, K; Wang, M, 2017) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 9.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| " We investigated whether telmisartan prevents WML progression in the imaging substudy of the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial." | 9.16 | Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. ( Blatchford, J; Demchuk, AM; Diehl, A; Diener, HC; Forsting, M; Gizewski, ER; Hermansson, K; Möller-Hartmann, C; Sacco, RL; Saver, JL; Wanke, I; Warach, S; Weber, R; Weimar, C, 2012) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 9.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "To study the prevalence and importance of aspirin resistance in patients with an evolving acute myocardial infarction (AMI) by use of the Platelet Function Analyzer-100." | 9.12 | Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. ( Haghfelt, T; Jørgensen, B; Korsholm, L; Licht, PB; Mickley, H; Poulsen, TS, 2007) |
| "Aspirin treatment did not significantly reduce the frequency of stroke progression." | 9.10 | Aspirin in the prevention of progressing stroke: a randomized controlled study. ( Britton, M; Leijd, B; Malmkvist, K; Rödén-Jüllig, A, 2003) |
| "In order to evaluate the effect of triflusal (2-acetyloxy-4-trifluoromethyl benzoic acid), an orally active antiplatelet agent, on arteriosclerosis progression, a pilot, parallel, double-dummy, double-blind clinical trial vs acetylsalicylic acid (ASA) was carried out in patients with subclinical atherosclerotic lesions." | 9.09 | Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound. ( Ambrosoli, L; Belcaro, G; Cesarone, MR; DeSanctis, MT; Fugazza, L; Girardello, R; Incandela, L; Laurora, G; Peracino, L; Poli, A, 1999) |
| "The prevalence and mean provocative dose of oral aspirin (MPDA) triggering respiratory reactions in people with asthma have been inconsistently reported, and the relationship between NSAID-exacerbated respiratory disease (NERD) and asthma morbidity was less well quantified." | 8.91 | NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. ( Donnan, PT; Guthrie, B; Jackson, C; Lipworth, BJ; Morales, DR; Santiago, VH, 2015) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 8.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "The effect of aspirin on the risk of hepatocellular carcinoma (HCC) remains unclear." | 7.88 | Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. ( Chang, J; Hwang, IC; Kim, K; Park, SM, 2018) |
| "To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients." | 7.88 | Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "The use of low-dose aspirin (acetylsalicylic acid [ASA]) has been suggested to attenuate growth of abdominal aortic aneurysms (AAAs), yet solid clinical evidence of this hypothesis is still missing." | 7.85 | Low-dose aspirin and rupture of abdominal aortic aneurysm. ( Behr-Rasmussen, C; Høgh, A; Johnsen, SP; Jørgensen, TM; Lindholt, JS; Wemmelund, H, 2017) |
| "A higher loading dose of aspirin (160-325 mg) can be beneficial in treating acute ischemic stroke, although there is an increased risk of minor bleeding." | 7.83 | To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. ( Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016) |
| "The impact of statins, aspirin and metformin use on recurrence-free (RFS) and overall survival (OS) of patients with biliary tract cancer (BTC) has not been evaluated." | 7.81 | Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer. ( Aneja, P; Horgan, AM; Knox, JJ; Le, LW; McKeever, E; McNamara, MG, 2015) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 7.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "To project the long-term cost-effectiveness of treating non-valvular atrial fibrillation (AF) patients for stroke prevention with rivaroxaban compared to warfarin in Portugal." | 7.80 | Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. ( Aguiar, C; Chatzitheofilou, I; Fonseca Santos, I; McLeod, E; Morais, J; Pereira, S, 2014) |
| "Tumor-associated inflammation is a driving force in several adult cancers and intake of low-dose aspirin has proven to reduce cancer incidence." | 7.79 | Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. ( Carlson, LM; Idborg, H; Jakobsson, PJ; Kogner, P; Rasmuson, A; Segerström, L; Sveinbjörnsson, B, 2013) |
| "To evaluate the recurrence-free survival (RFS) rate of patients taking cardioprotective aspirin after intravesical bacille Calmette-Guérin (BCG) for high-grade noninvasive urothelial carcinoma of the bladder, as preventing the recurrence of superficial bladder cancer might decrease patient morbidity and mortality from this disease, and nonsteroidal anti-inflammatory agents (NSAIDs) have shown promise in preclinical prevention through inhibition of the prostaglandin pathway and other mechanisms." | 7.75 | Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. ( Bruskewitz, RC; Gee, JR; Hedican, SP; Jarrard, DF; Leverson, GE; Messing, EM; Moon, TD; Nakada, SY, 2009) |
| "A sudden hearing loss in a woman on aspirin has uncovered a frequently neglected toxicological parameter." | 7.75 | Hearing loss in a woman on aspirin: the silent pharmacokinetic parameter. ( Koren, G, 2009) |
| "To investigate the effect of carnosine (CA), aminoguanidine (AG), and aspirin (ASA) drops, all inhibitors of glycation, on the development of diabetic cataract in rat." | 7.74 | Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats. ( Ding, Z; Guo, Y; Ha, W; Harding, JJ; Yan, H; Zhang, J, 2008) |
| "The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy." | 7.74 | The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. ( Assy, N; Hussein, O; Khalil, A; Luder, A; Paizi, M; Spira, G; Szvalb, S, 2007) |
| "Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis." | 7.74 | Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. ( Koellnberger, M; Konrad, I; Lorenz, R; Massberg, S; Orschiedt, L; Sauer, S; Schulz, C; Walter, U, 2008) |
| "COX-1-dependent eicosanoid formation accelerates atherogenesis, and low-dose aspirin reduces early atherosclerosis." | 7.73 | Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. ( Cyrus, T; Praticò, D; Tung, LX; Yao, Y, 2006) |
| "The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 7.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
| "The authors measured the presence and extent of asymptomatic microbleeds on gradient-recalled-echo MRI in 21 aspirin users who developed intracerebral hemorrhage and 21 aspirin users without history of intracerebral hemorrhage." | 7.72 | Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. ( Chan, YL; Gao, S; Lam, WW; Liu, JY; Wong, KS, 2003) |
| "The role of acetylation in the antiglycating and anticataract effects of aspirin (ASA) is explored by comparing ASA's effects with that of sodium salicylate (SS), a nonacetyl analog of ASA, on cataract development in diabetic rats." | 7.70 | Effect of aspirin and sodium salicylate on cataract development in diabetic rats. ( Kanagasabapathy, AS; Selvakumar, R; Shastri, GV; Thomas, K; Thomas, M; Victoria, AJ, 1998) |
| "We describe a boy with Kawasaki disease (KD) whose clinical course was marked by a rapid improvement upon treatment with intravenous immunoglobulin (IVIG) and oral aspirin, which - within 14 days - was followed by the development of a large pericardial effusion with symptoms of impending cardiac tamponade as part of a polyserositis syndrome (pleural effusions, ascites)." | 7.70 | Pulse methylprednisolone therapy for impending cardiac tamponade in immunoglobulin-resistant Kawasaki disease. ( Dahlem, PG; Kuijpers, TW; Lam, J; von Rosenstiel, IA, 1999) |
| "Non-alcoholic fatty liver disease (NAFLD) is now a public health issue worldwide, but no drug has yet received approval." | 5.48 | Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A ( Chen, J; Chen, W; Li, H; Mao, J; Wang, M; Wang, W; Zhang, H, 2018) |
| "Rheumatoid arthritis is a chronic inflammatory disease characterized by overproduction of inflammatory mediators along with undermined oxidative defensive mechanisms." | 5.40 | Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. ( El-Azab, MF; El-Sayed, RM; Moustafa, YM, 2014) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 5.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined." | 5.24 | ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. ( Backman, V; Carolan, PJ; Chan, AT; Chin, SM; Chung, DC; Colizzo, FP; Drew, DA; Flagg, M; Freedman, M; Gala, M; Garber, JJ; Gilpin, KK; Huttenhower, C; Kedrin, D; Khalili, H; Kwon, DS; Markowitz, SD; Milne, GL; Nishioka, NS; Parziale, M; Pond, E; Rawlings, CA; Richter, JM; Roy, HK; Schuck, MM; Staller, K; Stewart, K; Wang, M, 2017) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 5.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| " Aspirin or heparin was recommended for patients at high thrombosis risk." | 5.20 | Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). ( Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Giguere, JK; Johnson, J; Jung, SH; Leonard, JP; Pitcher, BN, 2015) |
| "We performed a secondary analysis from the Cilostazol in Acute Ischemic Stroke Treatment (CAIST) trial, which was a double-blinded, randomized, multicenter trial, assessing the noninferiority of cilostazol over aspirin within 48 hours of an acute ischemic stroke." | 5.19 | Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. ( Bae, HJ; Kang, DW; Kwon, HM; Lee, YS, 2014) |
| " We investigated whether telmisartan prevents WML progression in the imaging substudy of the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial." | 5.16 | Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. ( Blatchford, J; Demchuk, AM; Diehl, A; Diener, HC; Forsting, M; Gizewski, ER; Hermansson, K; Möller-Hartmann, C; Sacco, RL; Saver, JL; Wanke, I; Warach, S; Weber, R; Weimar, C, 2012) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 5.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "To study the prevalence and importance of aspirin resistance in patients with an evolving acute myocardial infarction (AMI) by use of the Platelet Function Analyzer-100." | 5.12 | Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. ( Haghfelt, T; Jørgensen, B; Korsholm, L; Licht, PB; Mickley, H; Poulsen, TS, 2007) |
| "During a 1-year treatment period, simvastatin, 20 mg/d, produced a sustained reduction of approximately one quarter in low-density lipoprotein cholesterol levels, with no evidence of toxicity, and aspirin, 100 mg/d, did not substantially increase the risk for a major bleeding episode." | 5.11 | First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. ( Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC, 2005) |
| "Aspirin treatment did not significantly reduce the frequency of stroke progression." | 5.10 | Aspirin in the prevention of progressing stroke: a randomized controlled study. ( Britton, M; Leijd, B; Malmkvist, K; Rödén-Jüllig, A, 2003) |
| "In order to evaluate the effect of triflusal (2-acetyloxy-4-trifluoromethyl benzoic acid), an orally active antiplatelet agent, on arteriosclerosis progression, a pilot, parallel, double-dummy, double-blind clinical trial vs acetylsalicylic acid (ASA) was carried out in patients with subclinical atherosclerotic lesions." | 5.09 | Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound. ( Ambrosoli, L; Belcaro, G; Cesarone, MR; DeSanctis, MT; Fugazza, L; Girardello, R; Incandela, L; Laurora, G; Peracino, L; Poli, A, 1999) |
| "A multicenter randomized clinical trial designed to assess the effect of photocoagulation and aspirin in patients with mild to severe nonproliferative or early proliferative diabetic retinopathy and/or macular edema." | 5.09 | Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25. ( Benson, WE; Burton, TC; Chew, EY; Csaky, K; Ferris, FL; Lindley, AA; Remaley, NA; Williams, GA, 1999) |
| "Aspirin-exacerbated respiratory disease is a chronic and treatment-resistant disease, characterized by the presence of eosinophilic rhinosinusitis, nasal polyposis, bronchial asthma, and nonsteroidal anti-inflammatory drugs hypersensitivity." | 4.98 | Aspirin exacerbated respiratory disease: Current topics and trends. ( Guaní-Guerra, E; Moreno-Paz, FJ; Rodríguez-Jiménez, JC; Terán, LM, 2018) |
| "Viral pericarditis is the most common cause of acute pericarditis and it is typically responsive to aspirin or nonsteroidal anti-inflammatory drugs." | 4.95 | Tuberculous and Infectious Pericarditis. ( Chang, SA, 2017) |
| "The strongest evidence is for non-steroidal anti-inflammatory drugs slowing polyp progression, notably Sulindac and aspirin in patients with familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer, respectively." | 4.95 | Chemoprevention of colorectal neoplasia. ( Eglinton, T; Eteuati, J; Frizelle, F; Hollington, P; Keenan, J; Wakeman, C, 2017) |
| "The prevalence and mean provocative dose of oral aspirin (MPDA) triggering respiratory reactions in people with asthma have been inconsistently reported, and the relationship between NSAID-exacerbated respiratory disease (NERD) and asthma morbidity was less well quantified." | 4.91 | NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. ( Donnan, PT; Guthrie, B; Jackson, C; Lipworth, BJ; Morales, DR; Santiago, VH, 2015) |
| "Asthma has many triggers including rhinosinusitis; allergy; irritants; medications (aspirin in aspirin-exacerbated respiratory disease); and obesity." | 4.90 | Identifying asthma triggers. ( Ferguson, BJ; McCarty, JC, 2014) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 4.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "The current standard of care for the treatment of arterial thrombosis includes anticoagulants and three classes of antiplatelet agents--aspirin, thienopyridines and glycoprotein IIb-IIIa antagonists." | 4.82 | Therapeutic approaches in arterial thrombosis. ( Andre, P; Conley, PB; Phillips, DR; Sinha, U, 2005) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "In patients with acute intracerebral hemorrhage, hematoma appearances on CT are associated with biomarkers of platelet activity and clopidogrel use prior to admission." | 4.12 | Antiplatelet Medications and Biomarkers of Hemostasis May Explain the Association of Hematoma Appearance and Subsequent Hematoma Expansion After Intracerebral Hemorrhage. ( Kwaan, H; Lindholm, PF; Luo, Y; Metcalf-Doetsch, W; Naidech, AM; Shin, HJ; Tang, M, 2022) |
| "Our previous trial acute dual study (ADS) reported that dual antiplatelet therapy (DAPT) using cilostazol and aspirin did not reduce the rate of short-term neurological worsening in non-cardioembolic stroke patients." | 4.02 | Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2021) |
| "Women with antiphospholipid antibodies (aPL) are at risk for pregnancy complications despite treatment with low molecular weight heparin (LMWH) or aspirin (ASA)." | 3.88 | Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies. ( Abrahams, VM; Bryce, E; Chamley, LW; Guller, S; Quao, ZC; Tong, M, 2018) |
| "Our findings suggest that concurrent use of glucocorticoids, ACE inhibitors, aspirin, NSAIDs, selective COX-2 inhibitors, digoxin, and opioids has little impact on breast cancer recurrence." | 3.88 | Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database. ( Ahern, TP; Christiansen, P; Cronin-Fenton, D; Damkier, P; Ejlertsen, B; Lash, TL; Sørensen, HT, 2018) |
| "The effect of aspirin on the risk of hepatocellular carcinoma (HCC) remains unclear." | 3.88 | Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. ( Chang, J; Hwang, IC; Kim, K; Park, SM, 2018) |
| "To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients." | 3.88 | Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "The use of low-dose aspirin (acetylsalicylic acid [ASA]) has been suggested to attenuate growth of abdominal aortic aneurysms (AAAs), yet solid clinical evidence of this hypothesis is still missing." | 3.85 | Low-dose aspirin and rupture of abdominal aortic aneurysm. ( Behr-Rasmussen, C; Høgh, A; Johnsen, SP; Jørgensen, TM; Lindholt, JS; Wemmelund, H, 2017) |
| "A higher loading dose of aspirin (160-325 mg) can be beneficial in treating acute ischemic stroke, although there is an increased risk of minor bleeding." | 3.83 | To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. ( Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016) |
| " Prior known oral NSAIDs hypersensitivity included aspirin (5), mefenamic acid (2), diclofenac (2), Synflex (2) and ibuprofen (1)." | 3.83 | Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link. ( Hsu, AAL; Tan, JHY, 2016) |
| "The impact of statins, aspirin and metformin use on recurrence-free (RFS) and overall survival (OS) of patients with biliary tract cancer (BTC) has not been evaluated." | 3.81 | Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer. ( Aneja, P; Horgan, AM; Knox, JJ; Le, LW; McKeever, E; McNamara, MG, 2015) |
| " CRSwNP was subdivided into allergic fungal rhinosinusitis (AFRS), aspirin-exacerbated respiratory disease (AERD), and other CRSwNP." | 3.80 | Impact of vitamin D deficiency upon clinical presentation in nasal polyposis. ( Mulligan, JK; Schlosser, RJ; Schmedes, GW; Soler, ZM; Storck, K, 2014) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 3.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "To project the long-term cost-effectiveness of treating non-valvular atrial fibrillation (AF) patients for stroke prevention with rivaroxaban compared to warfarin in Portugal." | 3.80 | Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. ( Aguiar, C; Chatzitheofilou, I; Fonseca Santos, I; McLeod, E; Morais, J; Pereira, S, 2014) |
| "To determine if there is a difference in clinical outcomes among non-muscle-invasive bladder cancer patients taking fibrin clot-inhibiting (FCI) medications (aspirin, clopidogrel, or warfarin) while receiving Bacillus Calmette-Guérin (BCG) therapy compared with their counterparts not taking anticoagulation." | 3.79 | The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer. ( Badalato, GM; Hruby, GW; Lipsky, MJ; McKiernan, JM; Motamedinia, P, 2013) |
| "Tumor-associated inflammation is a driving force in several adult cancers and intake of low-dose aspirin has proven to reduce cancer incidence." | 3.79 | Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. ( Carlson, LM; Idborg, H; Jakobsson, PJ; Kogner, P; Rasmuson, A; Segerström, L; Sveinbjörnsson, B, 2013) |
| "Aspirin-exacerbated respiratory disease (AERD) is a unique syndrome of airway inflammation that frequently occurs in patients with nasal polyposis, chronic sinusitis, and asthma." | 3.78 | Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. ( Stevenson, DD; White, AA, 2012) |
| "To evaluate the recurrence-free survival (RFS) rate of patients taking cardioprotective aspirin after intravesical bacille Calmette-Guérin (BCG) for high-grade noninvasive urothelial carcinoma of the bladder, as preventing the recurrence of superficial bladder cancer might decrease patient morbidity and mortality from this disease, and nonsteroidal anti-inflammatory agents (NSAIDs) have shown promise in preclinical prevention through inhibition of the prostaglandin pathway and other mechanisms." | 3.75 | Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. ( Bruskewitz, RC; Gee, JR; Hedican, SP; Jarrard, DF; Leverson, GE; Messing, EM; Moon, TD; Nakada, SY, 2009) |
| "A sudden hearing loss in a woman on aspirin has uncovered a frequently neglected toxicological parameter." | 3.75 | Hearing loss in a woman on aspirin: the silent pharmacokinetic parameter. ( Koren, G, 2009) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| "To investigate the effect of carnosine (CA), aminoguanidine (AG), and aspirin (ASA) drops, all inhibitors of glycation, on the development of diabetic cataract in rat." | 3.74 | Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats. ( Ding, Z; Guo, Y; Ha, W; Harding, JJ; Yan, H; Zhang, J, 2008) |
| "The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy." | 3.74 | The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. ( Assy, N; Hussein, O; Khalil, A; Luder, A; Paizi, M; Spira, G; Szvalb, S, 2007) |
| "Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis." | 3.74 | Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. ( Koellnberger, M; Konrad, I; Lorenz, R; Massberg, S; Orschiedt, L; Sauer, S; Schulz, C; Walter, U, 2008) |
| "COX-1-dependent eicosanoid formation accelerates atherogenesis, and low-dose aspirin reduces early atherosclerosis." | 3.73 | Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. ( Cyrus, T; Praticò, D; Tung, LX; Yao, Y, 2006) |
| "The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 3.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
| "The authors measured the presence and extent of asymptomatic microbleeds on gradient-recalled-echo MRI in 21 aspirin users who developed intracerebral hemorrhage and 21 aspirin users without history of intracerebral hemorrhage." | 3.72 | Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. ( Chan, YL; Gao, S; Lam, WW; Liu, JY; Wong, KS, 2003) |
| "The role of acetylation in the antiglycating and anticataract effects of aspirin (ASA) is explored by comparing ASA's effects with that of sodium salicylate (SS), a nonacetyl analog of ASA, on cataract development in diabetic rats." | 3.70 | Effect of aspirin and sodium salicylate on cataract development in diabetic rats. ( Kanagasabapathy, AS; Selvakumar, R; Shastri, GV; Thomas, K; Thomas, M; Victoria, AJ, 1998) |
| "We describe a boy with Kawasaki disease (KD) whose clinical course was marked by a rapid improvement upon treatment with intravenous immunoglobulin (IVIG) and oral aspirin, which - within 14 days - was followed by the development of a large pericardial effusion with symptoms of impending cardiac tamponade as part of a polyserositis syndrome (pleural effusions, ascites)." | 3.70 | Pulse methylprednisolone therapy for impending cardiac tamponade in immunoglobulin-resistant Kawasaki disease. ( Dahlem, PG; Kuijpers, TW; Lam, J; von Rosenstiel, IA, 1999) |
| "To study platelet aggregation (PA) in patients with left ventricular hypertrophy (LVH) in essential hypertension (EH) and hypertrophic cardiomyopathy (HTCM), and to assess aspirin treatment effects." | 3.70 | [Platelet aggregation in patients with various forms of left ventricular hypertrophy and its changes at long-term follow-up and treatment]. ( Gabbasov, ZA; Iurenev, AP; Riazanov, AS, 2000) |
| "Cilostazol treatment was associated with significantly lowered IMT in T2D patients compared to aspirin, independent of conventional cardiovascular risk factors." | 2.90 | Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness. ( Chun, M; Hong, S; Kang, J; Kim, D; Lee, K; Little, BB; Nam, M; Paik, S; Park, Y; Woo, J, 2019) |
| "Aspirin use was not associated significantly with progression to late AMD or its subtypes in either the AREDS or AREDS2." | 2.90 | The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20. ( Agrón, E; Aronow, ME; Chew, EY; Christen, WG; Clemons, TE; Keenan, TD; Wiley, HE, 2019) |
| "Aspirin treatment (100 mg/day) (n = 50) or usual therapy (n = 61)." | 2.87 | Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). ( Abad, S; Arroyo, D; Bernis, C; de Sequera, P; de Vinuesa, SG; Delgado, R; Fernández-Juárez, G; Goicoechea, M; Luño, J; Morales, E; Ortiz, A; Quiroga, B; Torres, A; Verdalles, U; Verde, E, 2018) |
| "Data from 140 men with prostate cancer enrolled in a Phase 2 clinical trial of selenium to prevent prostate cancer progression were analyzed to determine association between aspirin, other NSAIDs, or statin use with baseline serum prostate-specific antigen (PSA) levels and PSA velocity (rate of PSA change over time) using repeated measures over an average follow-up time of 3." | 2.75 | Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. ( Ahmann, FR; Algotar, AM; Hsu, CH; Nagle, RB; Ranger-Moore, J; Stratton, MS; Stratton, SP; Thompson, PA, 2010) |
| "Aspirin is a commonly used medication with anti-inflammatory and analgesic properties, and it is widely used to reduce the risk of ischaemic heart disease-related events and/or cerebrovascular accidents." | 2.72 | The multiple effects of aspirin in prostate cancer patients. ( Bryant, RJ; Joshi, SN; Murphy, EA; Olaniyi, P, 2021) |
| "Aspirin has been associated with adverse heart failure outcomes, probably because of a blunting interaction with angiotensin-converting enzyme (ACE) inhibitors." | 2.72 | Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure. ( Jug, B; Keber, I; Sabovic, M; Sebestjen, M, 2006) |
| "Although pharmacologic treatment for hyperlipidemia had the greatest favorable impact on the ratio over time, our data also show that maintaining an ideal weight and exercise have beneficial effects." | 2.71 | Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men. ( Buring, JE; Gaziano, JM; Levenson, JW; Scranton, R; Sesso, HD; Stampfer, MJ, 2004) |
| "Breast cancer is the most ubiquitous type of neoplasms among women worldwide." | 2.66 | Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions. ( Manoharan, R; Natarajan, SR; Ponnusamy, L; Thangaraj, K, 2020) |
| "Chronic obstructive pulmonary disease (COPD) is a heterogeneous multisystem disease, causing significant morbidity and mortality worldwide." | 2.66 | Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy. ( Ball, S; Mallah, H; Nugent, K; Parmar, K; Sekhon, J, 2020) |
| "Today, pregnancy is no longer considered impossible in women with lupus." | 2.53 | Pregnancy in women with systemic lupus erythematosus (SLE). ( Moroni, G; Ponticelli, C, 2016) |
| "Abdominal obesity, independently of gastroesophageal reflux disease symptoms, is associated with increased risk of Barrett's esophagus and this association is likely mediated by high levels of leptin and insulin." | 2.53 | Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. ( Thrift, AP, 2016) |
| " Careful attention must be paid to the dosing and potential teratogenicity of medications." | 2.52 | Pregnancy and Lupus Nephritis. ( Garovic, VD; Kattah, AG, 2015) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "Enlargement of an abdominal aortic aneurysm (AAA) is usually associated with the development of an intraluminal mural thrombus (ILT)." | 2.49 | Anti-platelet treatment of middle-sized abdominal aortic aneurysms. ( Björck, M; Lindholt, JS; Michel, JB, 2013) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "However, unlike stroke, treatment of hyperlipidemia with statin class drugs or treatment of blood clotting abnormalities with acetylsalicylic acid do not appear to have an effect on VaD incidence or progression." | 2.48 | Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. ( Baskys, A; Cheng, JX, 2012) |
| "Recurrent pericarditis are common and their management remains a matter of debate." | 2.47 | [What's new in recurrent pericarditis in 2011?]. ( Cacoub, P; Geri, G, 2011) |
| "Twenty-three children had varicella at age 1." | 2.43 | Post-varicella arteriopathy of childhood: natural history of vascular stenosis. ( Armstrong, D; deVeber, G; Domi, T; Lanthier, S, 2005) |
| "Women with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are subject to several complications during pregnancy, including reactivation of SLE, thrombosis, miscarriage, neonatal lupus, pregnancy-induced hypertension, pulmonary hypertension and drug toxicity." | 2.43 | [Systematic lupus erythematosus and antiphospholipid syndrome during pregnancy]. ( Khamashta, MA; Ruiz-Irastorza, G, 2006) |
| " Unlike selective COX-2 inhibitors, coadministration of licofelone and aspirin does not appear to be associated with an increase in gastrointestinal adverse events, at least under experimental conditions." | 2.42 | Safety of anti-inflammatory treatment--new ways of thinking. ( Brune, K, 2004) |
| "In the developed world, Kawasaki disease is currently the leading cause of pediatric acquired heart disease." | 2.42 | Recent developments and controversies in Kawasaki disease. ( Guzman-Cottrill, JA; Shulman, ST, 2004) |
| "Placental infarction due to thrombosis seems to be the most consistent event." | 2.40 | Fertility, pregnancy and the management of myeloproliferative disorders. ( Bergmann, L; Griesshammer, M; Pearson, T, 1998) |
| "Patients who take aspirin and sustain traumatic intracranial hemorrhage (tICH) are often transfused platelets in an effort to prevent bleeding progression." | 1.62 | Platelet Reactivity Testing for Aspirin Patients Who Sustain Traumatic Intracranial Hemorrhage. ( Eastman, DK; Pelaez, CA; Sidwell, RA; Spilman, SK; Tang, K, 2021) |
| " Long-term administration of acetylsalicylic acid (ASA) after desensitization has been used to mitigate these sequelae, but the optimal dose and balancing symptom relief and side effects remain unsettled." | 1.56 | Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid. ( Appel, H; Greve, J; Hahn, J; Hoffmann, TK; Lindemann, J; Petereit, F; Scheithauer, MO; Sommer, F; Veit, JA, 2020) |
| " ASA treatment also evoked an increase in platelet and granulocyte counts and decreased systemic NO bioavailability along with increased markers of systemic oxidant stress such as higher GSSG/lower GSH concentrations in RBC." | 1.56 | Unexpected effects of long-term treatment with acetylsalicylic acid on late phase of pulmonary metastasis in murine model of orthotopic breast cancer. ( Berkowicz, P; Chlopicki, S; Derszniak, K; Jasztal, A; Kieronska-Rudek, A; Kij, A; Matyjaszczyk-Gwarda, K; Proniewski, B; Przyborowski, K; Smeda, M; Sternak, M; Stojak, M, 2020) |
| "Gallbladder stones (cholecystolithiasis) are the main risk factor for gallbladder cancer (GBC), a lethal biliary malignancy with poor survival rates worldwide." | 1.56 | Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia. ( Arrese, M; Bizama, C; Espinoza, JA; Ferreccio, C; García, P; Gómez, N; González, X; Guevara, F; Kalergis, AM; Lobos-González, L; Miquel, JF; Muñoz-Durango, N; Roa, JC; Rosa, L; Saavedra, N; Villegas, J; Wichmann, IA, 2020) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "We found that it may be advisable for prostate cancer patients to take aspirin to improve their survival for both prostate cancer mortality and other mortality outcomes." | 1.51 | Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. ( Allard, CB; Chan, JM; Downer, MK; Giovannucci, E; Kenfield, SA; Mucci, LA; Preston, MA; Stampfer, MJ; Wilson, KM, 2019) |
| "Aspirin exposure was more common in stable VS than growing VS (22." | 1.48 | Aspirin does not prevent growth of vestibular schwannomas: A case-control study. ( Axon, P; Baker, C; Donnelly, N; Guilfoyle, M; Jefferies, S; John, D; MacKeith, S; Mannion, R; Tysome, JR; Wasson, J, 2018) |
| "In sum, in patients with AECOPD, aspirin use was associated with lower rates of in-hospital mortality and invasive mechanical ventilation use, and shorter length-of-stay." | 1.48 | The association of aspirin use with severity of acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study. ( Camargo, CA; Faridi, MK; Goto, T; Hasegawa, K, 2018) |
| "The participants were 5,696 adults with COPD with a first myocardial infarction (n = 2,850) or ischemic stroke (n = 3,010) and at least one acute exacerbation from the UK Clinical Practice Research Datalink with linked Hospital Episodes Statistics data." | 1.48 | Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. ( Connell, O; Douglas, I; Müllerová, H; Pearce, N; Quint, JK; Rothnie, KJ; Smeeth, L, 2018) |
| "Non-alcoholic fatty liver disease (NAFLD) is now a public health issue worldwide, but no drug has yet received approval." | 1.48 | Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A ( Chen, J; Chen, W; Li, H; Mao, J; Wang, M; Wang, W; Zhang, H, 2018) |
| "Aspirin consumption was associated with increased long-term mortality and MACE." | 1.48 | Are Prior Aspirin Users With ST-Elevation Myocardial Infarction at Increased Risk of Adverse Events and Worse Angiographic Features? ( Geraiely, B; Mortazavi, SH; Poorhosseini, H; Sadeghian, S; Sattarzadeh Badkoubeh, R, 2018) |
| "EHIT can lead to deep vein thrombosis/pulmonary embolism, which cause significant disability and, rarely, death." | 1.46 | Outcomes of a single-center experience with classification and treatment of endothermal heat-induced thrombosis after endovenous ablation. ( Chambers, CM; Cuff, RF; Korepta, LM; Mansour, MA; Slaikeu, JD; Watson, JJ; Wong, PY, 2017) |
| "Endoscopic features of eosinophilic esophagitis (EoE) are variable with at least 2 phenotypes." | 1.43 | Impact of Diagnostic Delay and Other Risk Factors on Eosinophilic Esophagitis Phenotype and Esophageal Diameter. ( Kumar, A; Lipka, S; Richter, JE, 2016) |
| " With the exception of CVA, all adverse events were significantly higher in positive Tn T group as compared to negative Tn T group." | 1.42 | Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD. ( Campo, G; Ceconi, C; Contoli, M; Guerzoni, F; Malagù, M; Napoli, N; Papi, A; Pavasini, R; Punzetti, S, 2015) |
| "Antiphospholipid syndrome is an autoimmune disorder characterized by the occurrence of venous and arterial thrombosis, as well as morbidity in pregnancy, in the presence of anti-phospholipid antibodies." | 1.42 | Elevated levels of antibodies against phosphatidylserine/prothrombin complex and/or cardiolipin associated with infection and recurrent purpura in a child: a forme fruste of antiphospholipid syndrome? ( Igarashi, T; Inaba, M; Katagiri, I; Kawana, S; Kinoshita, Y; Mayumi, N, 2015) |
| "Accelerated progression of residual hepatocellular carcinoma (HCC) after incomplete radiofrequency ablation (RFA) has been reported more frequently." | 1.42 | Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation. ( Ding, J; Duan, B; Jiang, T; Lu, S; Zhang, X, 2015) |
| "All patients with intracranial hemorrhage on initial CT with prehospital CAP therapy were included." | 1.40 | Repeat head computed tomography in anticoagulated traumatic brain injury patients: still warranted. ( Aziz, H; Friese, RS; Joseph, B; Kulvatunyou, N; O'Keeffe, T; Pandit, V; Rhee, P; Sadoun, M; Tang, A; Wynne, JL, 2014) |
| "Rheumatoid arthritis is a chronic inflammatory disease characterized by overproduction of inflammatory mediators along with undermined oxidative defensive mechanisms." | 1.40 | Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. ( El-Azab, MF; El-Sayed, RM; Moustafa, YM, 2014) |
| "We encountered an adolescent with Cogan syndrome complicated by aortitis and anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis." | 1.40 | Childhood Cogan syndrome with aortitis and anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. ( Enya, T; Izu, A; Miyazawa, T; Nishi, H; Okada, M; Sugimoto, K; Takemura, T, 2014) |
| "Liver fibrosis was assessed by histological evaluation." | 1.40 | Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation. ( Boëlle, PY; Chazouillères, O; Conti, F; Corpechot, C; Durand, F; Duvoux, C; Mackiewicz, V; Paradis, V; Poujol-Robert, A; Poupon, R; Wendum, D, 2014) |
| "Pancreatic cancer is a deadly disease killing 37,000 Americans each year." | 1.39 | A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. ( Grandhi, BK; Prabhu, S; Thakkar, A; Wang, J, 2013) |
| "Onyx HD-500 is a liquid embolic used to treat intracranial aneurysms." | 1.39 | Continued concern about parent vessel steno-occlusive progression with Onyx HD-500 and the utility of quantitative magnetic resonance imaging in serial assessment. ( Alaraj, A; Aletich, VA; Amin-Hanjani, S; Carlson, AP; Charbel, FT, 2013) |
| "Aspirin was negatively associated with high PSA velocity in model 1 (odds ratio (95% confidence interval): 0." | 1.38 | Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity. ( Ahmann, FR; Algotar, AM; Hsu, CH; Nagle, RB; Ranger-Moore, J; Stratton, MS; Stratton, SP; Thompson, PA, 2012) |
| "Furthermore, development of invasive pancreatic cancer in LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre transgenic mice was partially inhibited by enalapril and aspirin." | 1.36 | The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. ( Bartsch, DK; Buchholz, M; Chen, NM; Feldmann, G; Fendrich, V; Maitra, A; Neef, M; Slater, EP; Waldmann, J, 2010) |
| "Aspirin treatment decreased liver PGE(2) in treated hens as compared to control hens." | 1.35 | Dietary aspirin decreases the stage of ovarian cancer in the hen. ( Giles, JR; Johnson, PA; Urick, ME, 2009) |
| "We studied 103 patients with MCA stenosis using transcranial Doppler (TCD) and re-evaluated the TCD results at 6 months after the initial investigation and measured platelet aggregability for adenosine diphosphate (ADP) or arachidonic acid (AA)." | 1.35 | Factors related to progression of middle cerebral artery stenosis determined using transcranial Doppler ultrasonograhy. ( Cha, JK; Jeon, HW, 2008) |
| "We enrolled 35 patients with MPGN type 1 who had a normal creatinine clearance at the time of their first renal biopsy and divided them into 2 groups based on clinical status at the time of their most recent examination: 12 patients with normal urine test results and 12 patients with minor urinary abnormalities at the latest observation (group 1) and 7 patients with persistent nephropathy and 4 patients with renal insufficiency (group 2)." | 1.33 | Myeloid-related protein 8 expression on macrophages is a useful prognostic marker for renal dysfunction in children with MPGN type 1. ( Hosoya, M; Isome, M; Kawasaki, Y; Suzuki, H; Takahashi, A; Tanji, M, 2005) |
| "The metabolic syndrome is present in about half of individuals with symptomatic intracranial atherosclerotic disease and is associated with a substantially higher risk of major vascular events." | 1.33 | Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. ( Chimowitz, M; Lynn, MJ; Ovbiagele, B; Saver, JL, 2006) |
| "The number one or two cause of death in prostate cancer patients is also cardiovascular disease." | 1.32 | The use of complementary/preventive medicine to prevent prostate cancer recurrence/progression following definitive therapy. Part II--rapid review of dietary supplements. ( Moyad, MA, 2003) |
| "Two of the intracerebral hemorrhages occurred in the site where asymptomatic MBs were found at baseline." | 1.32 | Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. ( Fan, YH; Lam, WW; Mok, VC; Wong, KS; Zhang, L, 2003) |
| "Dyslipidemia is associated with macular exudates and vision loss." | 1.32 | Preventing diabetic retinopathy through control of systemic factors. ( Fong, D; Jain, A; Sarraf, D, 2003) |
| "Patients with complex coronary stenoses had a significantly (P<0." | 1.32 | Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. ( Christiansen, M; Cole, D; Cosin-Sales, J; Holt, DW; Kaminski, P; Kaski, JC; Overgaard, MT; Oxvig, C, 2004) |
| "Mutation of the adenomatous polyposis coli (APC) gene and the subsequent dysregulation of beta-catenin are well-documented abnormalities in familial adenomatous polyposis (FAP), as well as sporadic polyposis." | 1.31 | Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. ( Dedhar, S; Dupuis, B; Gallinger, S; Gray, V; Malik, S; Marotta, A; Owen, D; Salh, B; Sanghera, J; Tan, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (6.27) | 18.2507 |
| 2000's | 81 (31.76) | 29.6817 |
| 2010's | 129 (50.59) | 24.3611 |
| 2020's | 29 (11.37) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, M | 1 |
| Shin, HJ | 1 |
| Metcalf-Doetsch, W | 1 |
| Luo, Y | 1 |
| Lindholm, PF | 1 |
| Kwaan, H | 1 |
| Naidech, AM | 2 |
| Mwakyandile, T | 1 |
| Shayo, G | 1 |
| Mugusi, S | 1 |
| Sunguya, B | 1 |
| Sasi, P | 1 |
| Moshiro, C | 1 |
| Mugusi, F | 1 |
| Lyamuya, E | 1 |
| Sairam, S | 1 |
| Sureen, A | 1 |
| Gutierrez, J | 1 |
| Dang, TQ | 1 |
| Mishra, K | 1 |
| Eikelboom, JW | 3 |
| Jolly, SS | 2 |
| Belley-Cote, EP | 2 |
| Whitlock, RP | 2 |
| Rangarajan, S | 2 |
| Xu, L | 2 |
| Heenan, L | 2 |
| Bangdiwala, SI | 2 |
| Tarhuni, WM | 2 |
| Hassany, M | 2 |
| Kontsevaya, A | 1 |
| Harper, W | 2 |
| Sharma, SK | 1 |
| Lopez-Jaramillo, P | 2 |
| Dans, AL | 1 |
| Palileo-Villanueva, LM | 1 |
| Avezum, A | 2 |
| Pais, P | 1 |
| Xavier, D | 1 |
| Felix, C | 2 |
| Yusufali, A | 2 |
| Lopes, RD | 2 |
| Berwanger, O | 2 |
| Ali, Z | 1 |
| Wasserman, S | 2 |
| Anand, SS | 2 |
| Bosch, J | 2 |
| Choudhri, S | 2 |
| Farkouh, ME | 2 |
| Loeb, M | 2 |
| Yusuf, S | 2 |
| Luz Diaz, M | 1 |
| Diaz, R | 1 |
| Kumar Sharma, S | 1 |
| Almas, A | 1 |
| Drapkina, O | 1 |
| Schectman, JM | 1 |
| Zhang, N | 1 |
| Liu, Z | 1 |
| Luo, H | 1 |
| Wu, W | 1 |
| Nie, K | 1 |
| Cai, L | 1 |
| Tan, S | 1 |
| Chen, X | 1 |
| Huang, Y | 2 |
| Liu, J | 1 |
| Lv, M | 1 |
| Zhang, X | 3 |
| Fan, Y | 1 |
| Lin, Y | 1 |
| Ye, S | 1 |
| Liu, Y | 1 |
| Wu, L | 1 |
| Xu, J | 1 |
| Cavalcoli, F | 1 |
| Pusceddu, S | 1 |
| Zilli, A | 1 |
| Tamagno, G | 1 |
| Femia, D | 1 |
| Prinzi, N | 1 |
| Travers, J | 1 |
| Consonni, D | 1 |
| Ciafardini, C | 1 |
| Conte, D | 1 |
| Massironi, S | 1 |
| Hwang, IC | 2 |
| Lee, H | 1 |
| Yoon, YE | 1 |
| Choi, IS | 1 |
| Kim, HL | 1 |
| Chang, HJ | 1 |
| Lee, JY | 1 |
| Choi, JA | 1 |
| Kim, HJ | 1 |
| Cho, GY | 1 |
| Park, JB | 1 |
| Lee, SP | 1 |
| Kim, HK | 1 |
| Kim, YJ | 1 |
| Sohn, DW | 1 |
| Belcaro, G | 3 |
| Cesarone, MR | 3 |
| Scipione, C | 2 |
| Scipione, V | 2 |
| Dugall, M | 2 |
| Shu, H | 1 |
| Peterzan, P | 1 |
| Corsi, M | 1 |
| Luzzi, R | 1 |
| Hosoi, M | 1 |
| Feragalli, B | 2 |
| Cotellese, R | 2 |
| Hu, S | 1 |
| Maione, C | 1 |
| Welsh, RC | 1 |
| Peterson, ED | 1 |
| De Caterina, R | 1 |
| Bode, C | 1 |
| Gersh, B | 1 |
| Severo, MD | 1 |
| Bocchino, PP | 1 |
| De Filippo, O | 1 |
| Piroli, F | 1 |
| Scacciatella, P | 1 |
| Imazio, M | 1 |
| D'Ascenzo, F | 1 |
| De Ferrari, GM | 1 |
| Alvikas, J | 1 |
| Myers, SP | 1 |
| Wessel, CB | 1 |
| Okonkwo, DO | 1 |
| Joseph, B | 2 |
| Pelaez, C | 1 |
| Doberstein, C | 1 |
| Guillotte, AR | 1 |
| Rosengart, MR | 1 |
| Neal, MD | 1 |
| Hahn, J | 1 |
| Appel, H | 1 |
| Scheithauer, MO | 1 |
| Petereit, F | 1 |
| Greve, J | 1 |
| Lindemann, J | 1 |
| Hoffmann, TK | 1 |
| Veit, JA | 1 |
| Sommer, F | 1 |
| Smeda, M | 1 |
| Kij, A | 1 |
| Proniewski, B | 1 |
| Matyjaszczyk-Gwarda, K | 1 |
| Przyborowski, K | 1 |
| Jasztal, A | 1 |
| Derszniak, K | 1 |
| Berkowicz, P | 1 |
| Kieronska-Rudek, A | 1 |
| Stojak, M | 1 |
| Sternak, M | 1 |
| Chlopicki, S | 1 |
| Ponnusamy, L | 1 |
| Natarajan, SR | 1 |
| Thangaraj, K | 1 |
| Manoharan, R | 1 |
| Ramlakhan, KP | 1 |
| Johnson, MR | 1 |
| Roos-Hesselink, JW | 1 |
| Mitsuboshi, S | 1 |
| Yamada, H | 1 |
| Yamazaki, S | 1 |
| Kobayashi, M | 1 |
| Ueno, K | 1 |
| Nagai, K | 1 |
| Mallah, H | 1 |
| Ball, S | 1 |
| Sekhon, J | 1 |
| Parmar, K | 1 |
| Nugent, K | 1 |
| Fasano, S | 1 |
| Iacono, D | 1 |
| Riccardi, A | 1 |
| Ciccia, F | 1 |
| Valentini, G | 1 |
| Aoki, J | 1 |
| Iguchi, Y | 1 |
| Urabe, T | 1 |
| Yamagami, H | 1 |
| Todo, K | 1 |
| Fujimoto, S | 2 |
| Idomari, K | 1 |
| Kaneko, N | 1 |
| Iwanaga, T | 1 |
| Terasaki, T | 1 |
| Tanaka, R | 1 |
| Yamamoto, N | 1 |
| Tsujino, A | 1 |
| Nomura, K | 1 |
| Abe, K | 1 |
| Uno, M | 1 |
| Okada, Y | 2 |
| Matsuoka, H | 1 |
| Yamagata, S | 1 |
| Yamamoto, Y | 1 |
| Yonehara, T | 1 |
| Inoue, T | 2 |
| Yagita, Y | 2 |
| Kimura, K | 2 |
| Rosa, L | 1 |
| Lobos-González, L | 1 |
| Muñoz-Durango, N | 1 |
| García, P | 1 |
| Bizama, C | 1 |
| Gómez, N | 1 |
| González, X | 1 |
| Wichmann, IA | 1 |
| Saavedra, N | 1 |
| Guevara, F | 1 |
| Villegas, J | 1 |
| Arrese, M | 1 |
| Ferreccio, C | 1 |
| Kalergis, AM | 1 |
| Miquel, JF | 1 |
| Espinoza, JA | 1 |
| Roa, JC | 1 |
| Joshi, SN | 1 |
| Murphy, EA | 1 |
| Olaniyi, P | 1 |
| Bryant, RJ | 1 |
| Ho, JP | 1 |
| Galex, IA | 1 |
| Sadeghi, NB | 1 |
| Weledji, N | 1 |
| Cabello Bermudez, SI | 1 |
| Mitchell, BA | 1 |
| Bush, DM | 1 |
| Yap, E | 1 |
| Davis, NC | 1 |
| Catalino, MP | 1 |
| Godfrey, V | 1 |
| Nielsen, JN | 1 |
| Lee, YZ | 1 |
| Sasaki-Adams, DM | 1 |
| Davis, KAS | 1 |
| Bishara, D | 1 |
| Molokhia, M | 1 |
| Mueller, C | 1 |
| Perera, G | 1 |
| Stewart, RJ | 1 |
| Hybar, H | 1 |
| Saki, N | 1 |
| Maleknia, M | 1 |
| Moghaddasi, M | 1 |
| Bordbar, A | 1 |
| Naghavi, M | 1 |
| Eastman, DK | 1 |
| Spilman, SK | 1 |
| Tang, K | 1 |
| Sidwell, RA | 1 |
| Pelaez, CA | 1 |
| Sehanobish, E | 1 |
| Asad, M | 1 |
| Barbi, M | 1 |
| Porcelli, SA | 1 |
| Jerschow, E | 1 |
| Parker, WAE | 1 |
| Storey, RF | 1 |
| Kohanski, MA | 1 |
| Cohen, NA | 1 |
| Barrett, NA | 1 |
| Korepta, LM | 1 |
| Watson, JJ | 1 |
| Mansour, MA | 1 |
| Chambers, CM | 1 |
| Cuff, RF | 1 |
| Slaikeu, JD | 1 |
| Wong, PY | 1 |
| Kinsella, JA | 1 |
| Oliver Tobin, W | 1 |
| Tierney, S | 1 |
| Feeley, TM | 1 |
| Egan, B | 1 |
| Coughlan, T | 1 |
| Ronan Collins, D | 1 |
| O'Neill, D | 1 |
| Harbison, JA | 1 |
| Doherty, CP | 1 |
| Madhavan, P | 1 |
| Moore, DJ | 1 |
| O'Neill, SM | 1 |
| Colgan, MP | 1 |
| Saqqur, M | 1 |
| Murphy, RP | 1 |
| Moran, N | 1 |
| Hamilton, G | 1 |
| McCabe, DJH | 1 |
| Violi, F | 2 |
| Targher, G | 1 |
| Vestri, A | 1 |
| Carnevale, R | 1 |
| Averna, M | 1 |
| Farcomeni, A | 1 |
| Lenzi, A | 1 |
| Angelico, F | 1 |
| Cipollone, F | 1 |
| Pastori, D | 1 |
| Chang, SA | 1 |
| Quao, ZC | 1 |
| Tong, M | 1 |
| Bryce, E | 1 |
| Guller, S | 1 |
| Chamley, LW | 1 |
| Abrahams, VM | 1 |
| Beloncle, F | 1 |
| Mercat, A | 1 |
| Cronin-Fenton, D | 1 |
| Lash, TL | 1 |
| Ahern, TP | 1 |
| Damkier, P | 1 |
| Christiansen, P | 1 |
| Ejlertsen, B | 1 |
| Sørensen, HT | 1 |
| Ferrari, C | 1 |
| Lombardi, G | 1 |
| Polito, C | 1 |
| Lucidi, G | 1 |
| Bagnoli, S | 1 |
| Piaceri, I | 1 |
| Nacmias, B | 1 |
| Berti, V | 1 |
| Rizzuto, D | 1 |
| Fratiglioni, L | 1 |
| Sorbi, S | 1 |
| Aaron, CP | 1 |
| Schwartz, JE | 1 |
| Hoffman, EA | 1 |
| Angelini, E | 1 |
| Austin, JHM | 1 |
| Cushman, M | 1 |
| Jacobs, DR | 1 |
| Kaufman, JD | 1 |
| Laine, A | 1 |
| Smith, LJ | 1 |
| Yang, J | 1 |
| Watson, KE | 1 |
| Tracy, RP | 1 |
| Barr, RG | 1 |
| MacKeith, S | 1 |
| Wasson, J | 1 |
| Baker, C | 1 |
| Guilfoyle, M | 1 |
| John, D | 1 |
| Donnelly, N | 1 |
| Mannion, R | 1 |
| Jefferies, S | 1 |
| Axon, P | 1 |
| Tysome, JR | 1 |
| Rodríguez-Jiménez, JC | 1 |
| Moreno-Paz, FJ | 1 |
| Terán, LM | 1 |
| Guaní-Guerra, E | 1 |
| Saji, N | 1 |
| Tone, S | 1 |
| Murotani, K | 1 |
| Sakurai, T | 1 |
| Goto, T | 1 |
| Faridi, MK | 1 |
| Camargo, CA | 1 |
| Hasegawa, K | 1 |
| Gregg, LP | 1 |
| Hedayati, SS | 1 |
| Chang, J | 1 |
| Kim, K | 1 |
| Park, SM | 1 |
| Rothnie, KJ | 1 |
| Connell, O | 1 |
| Müllerová, H | 1 |
| Smeeth, L | 1 |
| Pearce, N | 1 |
| Douglas, I | 1 |
| Quint, JK | 1 |
| Wang, W | 1 |
| Chen, J | 1 |
| Mao, J | 1 |
| Li, H | 3 |
| Wang, M | 2 |
| Zhang, H | 1 |
| Chen, W | 1 |
| Lin, J | 1 |
| Han, Z | 1 |
| Wang, C | 3 |
| Yi, X | 1 |
| Chai, Z | 1 |
| Zhou, Q | 1 |
| Huang, R | 1 |
| Mathew, RO | 1 |
| Gosmanova, EO | 1 |
| Sidhu, MS | 1 |
| Goicoechea, M | 1 |
| de Vinuesa, SG | 1 |
| Quiroga, B | 1 |
| Verde, E | 1 |
| Bernis, C | 1 |
| Morales, E | 1 |
| Fernández-Juárez, G | 1 |
| de Sequera, P | 1 |
| Verdalles, U | 1 |
| Delgado, R | 1 |
| Torres, A | 1 |
| Arroyo, D | 1 |
| Abad, S | 1 |
| Ortiz, A | 1 |
| Luño, J | 1 |
| Godfrey, AL | 1 |
| Campbell, PJ | 1 |
| MacLean, C | 1 |
| Buck, G | 1 |
| Cook, J | 1 |
| Temple, J | 1 |
| Wilkins, BS | 1 |
| Wheatley, K | 1 |
| Nangalia, J | 1 |
| Grinfeld, J | 1 |
| McMullin, MF | 1 |
| Forsyth, C | 1 |
| Kiladjian, JJ | 1 |
| Green, AR | 2 |
| Harrison, CN | 1 |
| Bobolea, I | 2 |
| Del Pozo, V | 1 |
| Sanz, V | 1 |
| Cabañas, R | 1 |
| Fiandor, A | 1 |
| Alfonso-Carrillo, C | 1 |
| Salcedo, MÁ | 1 |
| Heredia Revuelto, R | 1 |
| Quirce, S | 2 |
| Tefferi, A | 5 |
| Barbui, T | 4 |
| Geraiely, B | 1 |
| Poorhosseini, H | 1 |
| Sadeghian, S | 1 |
| Sattarzadeh Badkoubeh, R | 1 |
| Mortazavi, SH | 1 |
| Day, AM | 1 |
| Hammill, AM | 1 |
| Juhász, C | 1 |
| Pinto, AL | 1 |
| Roach, ES | 1 |
| McCulloch, CE | 1 |
| Comi, AM | 2 |
| Downer, MK | 2 |
| Allard, CB | 2 |
| Preston, MA | 2 |
| Wilson, KM | 1 |
| Kenfield, SA | 1 |
| Chan, JM | 1 |
| Mucci, LA | 2 |
| Giovannucci, E | 1 |
| Stampfer, MJ | 3 |
| Greenberg, B | 1 |
| Neaton, JD | 1 |
| Anker, SD | 1 |
| Byra, WM | 1 |
| Cleland, JGF | 1 |
| Deng, H | 1 |
| Fu, M | 1 |
| La Police, DA | 1 |
| Lam, CSP | 1 |
| Mehra, MR | 1 |
| Nessel, CC | 1 |
| Spiro, TE | 1 |
| van Veldhuisen, DJ | 1 |
| Vanden Boom, CM | 1 |
| Zannad, F | 1 |
| Hong, S | 1 |
| Nam, M | 1 |
| Little, BB | 1 |
| Paik, S | 1 |
| Lee, K | 1 |
| Woo, J | 1 |
| Kim, D | 1 |
| Kang, J | 1 |
| Chun, M | 1 |
| Park, Y | 1 |
| Simon, TG | 2 |
| Henson, J | 1 |
| Osganian, S | 1 |
| Masia, R | 1 |
| Chan, AT | 2 |
| Chung, RT | 1 |
| Corey, KE | 2 |
| Vilar-Gomez, E | 1 |
| Chalasani, N | 1 |
| Keenan, TD | 1 |
| Wiley, HE | 1 |
| Agrón, E | 1 |
| Aronow, ME | 1 |
| Christen, WG | 1 |
| Clemons, TE | 1 |
| Chew, EY | 2 |
| Choe, KS | 1 |
| Liauw, SL | 1 |
| Poredos, P | 2 |
| Jezovnik, MK | 2 |
| Alvarez-Larrán, A | 1 |
| Cervantes, F | 1 |
| Besses, C | 1 |
| Lipsky, MJ | 1 |
| Badalato, GM | 1 |
| Motamedinia, P | 1 |
| Hruby, GW | 1 |
| McKiernan, JM | 1 |
| Conrad, MF | 2 |
| Boulom, V | 1 |
| Baloum, V | 1 |
| Mukhopadhyay, S | 1 |
| Garg, A | 1 |
| Patel, VI | 2 |
| Cambria, RP | 2 |
| D'Amelio, M | 1 |
| Terruso, V | 1 |
| Famoso, G | 1 |
| Di Benedetto, N | 1 |
| Realmuto, S | 1 |
| Valentino, F | 1 |
| Ragonese, P | 1 |
| Savettieri, G | 1 |
| Aridon, P | 1 |
| Pecci, A | 1 |
| Croci, G | 1 |
| Balduini, CL | 1 |
| Boveri, E | 1 |
| Grandhi, BK | 1 |
| Thakkar, A | 1 |
| Wang, J | 1 |
| Prabhu, S | 1 |
| McCarty, JC | 1 |
| Ferguson, BJ | 1 |
| Qian, Y | 1 |
| Bi, Q | 1 |
| Sadoun, M | 1 |
| Aziz, H | 1 |
| Tang, A | 1 |
| Wynne, JL | 1 |
| Pandit, V | 1 |
| Kulvatunyou, N | 1 |
| O'Keeffe, T | 1 |
| Friese, RS | 1 |
| Rhee, P | 1 |
| Schlosser, RJ | 1 |
| Soler, ZM | 1 |
| Schmedes, GW | 1 |
| Storck, K | 1 |
| Mulligan, JK | 1 |
| Kwon, HM | 1 |
| Lee, YS | 2 |
| Bae, HJ | 2 |
| Kang, DW | 1 |
| El-Sayed, RM | 1 |
| Moustafa, YM | 1 |
| El-Azab, MF | 1 |
| Servello, A | 1 |
| Andreozzi, P | 1 |
| Bechini, F | 1 |
| De Angelis, R | 1 |
| Pontecorvo, ML | 1 |
| Vulcano, A | 1 |
| Cerra, E | 1 |
| Vigliotta, MT | 1 |
| Artini, M | 1 |
| Selan, L | 1 |
| Ettorre, E | 1 |
| Sugimoto, K | 1 |
| Miyazawa, T | 1 |
| Nishi, H | 1 |
| Izu, A | 1 |
| Enya, T | 1 |
| Okada, M | 1 |
| Takemura, T | 1 |
| Michalczyk, MJ | 1 |
| Opalacz, A | 1 |
| LaMuraglia, GM | 1 |
| Mastalerz, L | 1 |
| Celejewska-Wójcik, N | 1 |
| Wójcik, K | 1 |
| Gielicz, A | 1 |
| Januszek, R | 1 |
| Cholewa, A | 1 |
| Stręk, P | 1 |
| Sanak, M | 1 |
| Poujol-Robert, A | 1 |
| Boëlle, PY | 1 |
| Conti, F | 1 |
| Durand, F | 1 |
| Duvoux, C | 1 |
| Wendum, D | 1 |
| Paradis, V | 1 |
| Mackiewicz, V | 1 |
| Chazouillères, O | 1 |
| Corpechot, C | 1 |
| Poupon, R | 1 |
| Agmadova, ZM | 1 |
| Kallaeva, AN | 1 |
| Une, D | 1 |
| Al-Atassi, T | 1 |
| Kulik, A | 1 |
| Voisine, P | 1 |
| Le May, M | 1 |
| Ruel, M | 1 |
| Morais, J | 1 |
| Aguiar, C | 1 |
| McLeod, E | 1 |
| Chatzitheofilou, I | 1 |
| Fonseca Santos, I | 1 |
| Pereira, S | 1 |
| Sánchez-Borges, M | 1 |
| Caballero-Fonseca, F | 1 |
| Capriles-Hulett, A | 1 |
| González-Aveledo, L | 1 |
| Cavkaytar, O | 1 |
| Arik Yilmaz, E | 1 |
| Buyuktiryaki, B | 1 |
| Sekerel, BE | 1 |
| Sackesen, C | 1 |
| Soyer, OU | 1 |
| Lipka, S | 1 |
| Kumar, A | 1 |
| Richter, JE | 1 |
| Campo, G | 1 |
| Pavasini, R | 1 |
| Malagù, M | 1 |
| Punzetti, S | 1 |
| Napoli, N | 1 |
| Guerzoni, F | 1 |
| Papi, A | 1 |
| Ceconi, C | 1 |
| Contoli, M | 1 |
| Nishimiya, K | 1 |
| Matsumoto, Y | 1 |
| Uzuka, H | 1 |
| Oyama, K | 1 |
| Tanaka, A | 1 |
| Taruya, A | 1 |
| Ogata, T | 1 |
| Hirano, M | 1 |
| Shindo, T | 1 |
| Hanawa, K | 1 |
| Hasebe, Y | 1 |
| Hao, K | 1 |
| Tsuburaya, R | 1 |
| Takahashi, J | 1 |
| Miyata, S | 1 |
| Ito, K | 1 |
| Akasaka, T | 1 |
| Shimokawa, H | 1 |
| Morales, DR | 1 |
| Guthrie, B | 1 |
| Lipworth, BJ | 1 |
| Jackson, C | 1 |
| Donnan, PT | 1 |
| Santiago, VH | 1 |
| Korsaga-Somé, N | 1 |
| Maruani, A | 1 |
| Abdo, I | 1 |
| Favrais, G | 1 |
| Lorette, G | 1 |
| Albers, A | 1 |
| Carli, A | 1 |
| Routy, B | 1 |
| Harvey, EJ | 1 |
| Séguin, C | 1 |
| Leonard, JP | 1 |
| Jung, SH | 1 |
| Johnson, J | 1 |
| Pitcher, BN | 1 |
| Bartlett, NL | 1 |
| Blum, KA | 1 |
| Czuczman, M | 1 |
| Giguere, JK | 1 |
| Cheson, BD | 1 |
| Stein, BL | 1 |
| Oh, ST | 1 |
| Berenzon, D | 1 |
| Hobbs, GS | 1 |
| Kremyanskaya, M | 1 |
| Rampal, RK | 1 |
| Abboud, CN | 1 |
| Adler, K | 1 |
| Heaney, ML | 1 |
| Jabbour, EJ | 1 |
| Komrokji, RS | 1 |
| Moliterno, AR | 1 |
| Ritchie, EK | 1 |
| Rice, L | 1 |
| Mascarenhas, J | 1 |
| Hoffman, R | 1 |
| Yokooji, T | 1 |
| Matsuo, H | 1 |
| Kinoshita, Y | 1 |
| Mayumi, N | 1 |
| Inaba, M | 1 |
| Igarashi, T | 1 |
| Katagiri, I | 1 |
| Kawana, S | 1 |
| Assad, M | 1 |
| Coffin-Pichonnet, S | 1 |
| Billotte, C | 1 |
| Denion, É | 1 |
| Kattah, AG | 1 |
| Garovic, VD | 1 |
| Lowthian, JA | 1 |
| Britt, CJ | 1 |
| Rance, G | 1 |
| Lin, FR | 1 |
| Woods, RL | 1 |
| Wolfe, R | 1 |
| Nelson, MR | 1 |
| Dillon, HA | 1 |
| Ward, S | 1 |
| Reid, CM | 1 |
| Lockery, JE | 1 |
| Nguyen, TT | 1 |
| McNeil, JJ | 1 |
| Storey, E | 1 |
| Wakeman, C | 1 |
| Keenan, J | 1 |
| Eteuati, J | 1 |
| Hollington, P | 1 |
| Eglinton, T | 1 |
| Frizelle, F | 1 |
| Machado-Carvalho, L | 1 |
| Torres, R | 1 |
| Perez-Gonzalez, M | 1 |
| Alobid, I | 1 |
| Mullol, J | 1 |
| Pujols, L | 1 |
| Roca-Ferrer, J | 1 |
| Picado, C | 1 |
| Jiang, T | 1 |
| Ding, J | 1 |
| Duan, B | 1 |
| Lu, S | 1 |
| McNamara, MG | 1 |
| Aneja, P | 1 |
| Le, LW | 1 |
| Horgan, AM | 1 |
| McKeever, E | 1 |
| Knox, JJ | 1 |
| Dake, MD | 1 |
| Ansel, GM | 1 |
| Jaff, MR | 1 |
| Ohki, T | 1 |
| Saxon, RR | 1 |
| Smouse, HB | 1 |
| Machan, LS | 1 |
| Snyder, SA | 1 |
| O'Leary, EE | 1 |
| Ragheb, AO | 1 |
| Zeller, T | 1 |
| Li, Z | 1 |
| Wang, Y | 2 |
| Zhao, X | 1 |
| Liu, L | 1 |
| Wang, D | 1 |
| Meng, X | 1 |
| Pan, Y | 1 |
| Wang, X | 1 |
| Yang, X | 1 |
| Zhang, C | 1 |
| Jing, J | 1 |
| Xian, Y | 1 |
| Johnston, SC | 1 |
| Goldstein, JL | 1 |
| Scheiman, JM | 1 |
| Fort, JG | 1 |
| Whellan, DJ | 1 |
| Moroni, G | 1 |
| Ponticelli, C | 1 |
| Singla, N | 1 |
| Haddad, AQ | 1 |
| Passoni, NM | 1 |
| Meissner, M | 1 |
| Lotan, Y | 1 |
| Thrift, AP | 1 |
| Piazuelo, E | 1 |
| Esquivias, P | 1 |
| De Martino, A | 1 |
| Cebrián, C | 1 |
| Conde, B | 1 |
| Santander, S | 1 |
| Emperador, S | 1 |
| García-González, MA | 1 |
| Carrera-Lasfuentes, P | 1 |
| Lanas, A | 1 |
| Su, TH | 1 |
| Chan, YL | 2 |
| Lee, JD | 1 |
| Lee, M | 1 |
| Lin, LC | 1 |
| Wen, YW | 1 |
| Lee, TH | 1 |
| Dunn, NM | 1 |
| Katial, RK | 1 |
| Wemmelund, H | 1 |
| Jørgensen, TM | 1 |
| Høgh, A | 1 |
| Behr-Rasmussen, C | 1 |
| Johnsen, SP | 1 |
| Lindholt, JS | 2 |
| Tan, JHY | 1 |
| Hsu, AAL | 1 |
| Michalska-Małecka, K | 1 |
| Regucka, A | 1 |
| Śpiewak, D | 1 |
| Sosnowska-Pońska, M | 1 |
| Niewiem, A | 1 |
| Drew, DA | 1 |
| Chin, SM | 1 |
| Gilpin, KK | 1 |
| Parziale, M | 1 |
| Pond, E | 1 |
| Schuck, MM | 1 |
| Stewart, K | 1 |
| Flagg, M | 1 |
| Rawlings, CA | 1 |
| Backman, V | 1 |
| Carolan, PJ | 1 |
| Chung, DC | 1 |
| Colizzo, FP | 1 |
| Freedman, M | 1 |
| Gala, M | 1 |
| Garber, JJ | 1 |
| Huttenhower, C | 1 |
| Kedrin, D | 1 |
| Khalili, H | 1 |
| Kwon, DS | 1 |
| Markowitz, SD | 1 |
| Milne, GL | 1 |
| Nishioka, NS | 2 |
| Richter, JM | 1 |
| Roy, HK | 1 |
| Staller, K | 1 |
| Gaziano, JM | 3 |
| Batista, JL | 1 |
| Gangat, N | 1 |
| Conen, D | 1 |
| Glynn, RJ | 1 |
| Buring, JE | 2 |
| Ridker, PM | 1 |
| Zee, RY | 1 |
| Alberts, MJ | 2 |
| Hur, C | 2 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Gazelle, GS | 2 |
| Belch, J | 1 |
| MacCuish, A | 1 |
| Campbell, I | 1 |
| Cobbe, S | 1 |
| Taylor, R | 1 |
| Prescott, R | 1 |
| Lee, R | 1 |
| Bancroft, J | 1 |
| MacEwan, S | 1 |
| Shepherd, J | 1 |
| Macfarlane, P | 1 |
| Morris, A | 1 |
| Jung, R | 1 |
| Kelly, C | 1 |
| Connacher, A | 1 |
| Peden, N | 1 |
| Jamieson, A | 1 |
| Matthews, D | 1 |
| Leese, G | 1 |
| McKnight, J | 1 |
| O'Brien, I | 1 |
| Semple, C | 1 |
| Petrie, J | 1 |
| Gordon, D | 1 |
| Pringle, S | 1 |
| MacWalter, R | 1 |
| Urick, ME | 1 |
| Giles, JR | 1 |
| Johnson, PA | 1 |
| Gee, JR | 1 |
| Jarrard, DF | 1 |
| Bruskewitz, RC | 1 |
| Moon, TD | 1 |
| Hedican, SP | 1 |
| Leverson, GE | 1 |
| Nakada, SY | 1 |
| Messing, EM | 1 |
| Yan, H | 1 |
| Guo, Y | 1 |
| Zhang, J | 1 |
| Ding, Z | 1 |
| Ha, W | 1 |
| Harding, JJ | 1 |
| Koren, G | 1 |
| Richard, S | 1 |
| Anxionnat, R | 1 |
| Delaunay, C | 1 |
| Ducrocq, X | 1 |
| Nancy, C | 1 |
| Günther, C | 1 |
| Meurer, M | 1 |
| Stein, A | 1 |
| Viehweg, A | 1 |
| Lee-Kirsch, MA | 1 |
| Richard, E | 1 |
| Kuiper, R | 1 |
| Dijkgraaf, MG | 1 |
| Van Gool, WA | 1 |
| Castells, M | 1 |
| Scher, AI | 1 |
| Lipton, RB | 1 |
| Stewart, WF | 1 |
| Bigal, M | 1 |
| Bendok, BR | 1 |
| Garg, RK | 1 |
| Bernstein, RA | 1 |
| Bleck, TP | 1 |
| Batjer, HH | 1 |
| Fendrich, V | 1 |
| Chen, NM | 1 |
| Neef, M | 1 |
| Waldmann, J | 1 |
| Buchholz, M | 1 |
| Feldmann, G | 1 |
| Slater, EP | 1 |
| Maitra, A | 1 |
| Bartsch, DK | 1 |
| Stolk, P | 1 |
| Souverein, PC | 1 |
| Wilting, I | 1 |
| Leufkens, HG | 1 |
| Klein, DF | 1 |
| Rapoport, SI | 1 |
| Heerdink, ER | 1 |
| Dörr, J | 1 |
| Radbruch, H | 1 |
| Bock, M | 1 |
| Wuerfel, J | 1 |
| Brüggemann, A | 1 |
| Wandinger, KP | 1 |
| Zeise, D | 1 |
| Pfueller, CF | 1 |
| Zipp, F | 1 |
| Paul, F | 1 |
| Beer, PA | 1 |
| Lønborg, J | 1 |
| Kelbaek, H | 1 |
| Vejlstrup, N | 1 |
| Jørgensen, E | 1 |
| Helqvist, S | 1 |
| Saunamäki, K | 1 |
| Clemmensen, P | 1 |
| Holmvang, L | 1 |
| Treiman, M | 1 |
| Jensen, JS | 1 |
| Engstrøm, T | 1 |
| Barranco, P | 1 |
| Larco, JI | 1 |
| Prior, N | 1 |
| López-Serrano, MC | 1 |
| Algotar, AM | 2 |
| Thompson, PA | 2 |
| Ranger-Moore, J | 2 |
| Stratton, MS | 2 |
| Hsu, CH | 2 |
| Ahmann, FR | 2 |
| Nagle, RB | 2 |
| Stratton, SP | 2 |
| Sallustio, F | 1 |
| Di Legge, S | 1 |
| Rossi, C | 1 |
| Stanzione, P | 1 |
| Hayeck, TJ | 1 |
| Yeh, JM | 1 |
| Richards, EM | 1 |
| Richards, EB | 1 |
| Spechler, SJ | 1 |
| Kong, CY | 1 |
| Landolfi, R | 3 |
| Nicolazzi, MA | 1 |
| Porfidia, A | 1 |
| Di Gennaro, L | 2 |
| Shigematsu, H | 1 |
| Nishibe, T | 1 |
| Obitsu, Y | 1 |
| Matsuzaki, K | 1 |
| Ishida, A | 1 |
| Miyata, T | 1 |
| Shindo, S | 1 |
| Hida, K | 1 |
| Ohta, T | 1 |
| Ando, M | 1 |
| Kawasaki, T | 1 |
| Yasugi, T | 1 |
| Matsumoto, T | 1 |
| Kuo, HW | 1 |
| Tsai, SS | 1 |
| Tiao, MM | 1 |
| Liu, YC | 1 |
| Lee, IM | 1 |
| Yang, CY | 1 |
| Ruggeri, M | 2 |
| Finotto, S | 1 |
| Fortuna, S | 1 |
| Rodeghiero, F | 1 |
| Ahn, CM | 1 |
| Hong, SJ | 1 |
| Park, JH | 1 |
| Kim, JS | 2 |
| Lim, DS | 1 |
| Masumura, Y | 1 |
| Ueda, Y | 1 |
| Matsuo, K | 1 |
| Akazawa, Y | 1 |
| Nishio, M | 1 |
| Hirata, A | 1 |
| Kashiwase, K | 1 |
| Nemoto, T | 1 |
| Kashiyama, T | 1 |
| Wada, M | 1 |
| Muller, JE | 1 |
| Kodama, K | 1 |
| Gravitz, L | 1 |
| Geri, G | 1 |
| Cacoub, P | 1 |
| Nandish, S | 1 |
| Wyatt, J | 1 |
| Bailon, O | 1 |
| Smith, M | 1 |
| Oliveros, R | 1 |
| Chilton, R | 1 |
| Gris, JC | 1 |
| Chauleur, C | 1 |
| Molinari, N | 1 |
| Marès, P | 1 |
| Fabbro-Peray, P | 1 |
| Quéré, I | 1 |
| Lefrant, JY | 1 |
| Haddad, B | 1 |
| Dauzat, M | 1 |
| Larsen, SB | 1 |
| Neergaard-Petersen, S | 1 |
| Grove, EL | 1 |
| Kristensen, SD | 1 |
| Hvas, AM | 1 |
| Vinod, J | 1 |
| Vadada, D | 1 |
| Korelitz, BI | 1 |
| Sonpal, N | 1 |
| Panagopoulos, G | 1 |
| Baiocco, P | 1 |
| Levitt, JE | 1 |
| Matthay, MA | 1 |
| Sanders, DS | 1 |
| Grabsch, H | 1 |
| Harrison, R | 1 |
| Bateman, A | 1 |
| Going, J | 1 |
| Goldin, R | 1 |
| Mapstone, N | 1 |
| Novelli, M | 1 |
| Walker, MM | 1 |
| Jankowski, J | 1 |
| Björck, M | 1 |
| Michel, JB | 1 |
| Weber, R | 1 |
| Weimar, C | 1 |
| Blatchford, J | 1 |
| Hermansson, K | 1 |
| Wanke, I | 1 |
| Möller-Hartmann, C | 1 |
| Gizewski, ER | 1 |
| Forsting, M | 1 |
| Demchuk, AM | 1 |
| Sacco, RL | 1 |
| Saver, JL | 2 |
| Warach, S | 1 |
| Diener, HC | 1 |
| Diehl, A | 1 |
| Baskys, A | 1 |
| Cheng, JX | 1 |
| Lopez, J | 1 |
| Yeom, KW | 1 |
| Comi, A | 1 |
| Van Haren, K | 1 |
| Vendrell, M | 1 |
| Valero, R | 1 |
| Mercadal, J | 1 |
| Enseñat, J | 1 |
| Fábregas, N | 1 |
| Albini, A | 1 |
| Tosetti, F | 1 |
| Li, VW | 1 |
| Noonan, DM | 1 |
| Li, WW | 1 |
| Liu, W | 1 |
| Liu, R | 1 |
| Sun, W | 1 |
| Peng, Q | 1 |
| Zhang, W | 1 |
| Xu, E | 1 |
| Cheng, Y | 1 |
| Ding, M | 1 |
| Li, Y | 1 |
| Hong, Z | 1 |
| Wu, J | 1 |
| Zeng, J | 1 |
| Yao, C | 1 |
| Rao, CV | 1 |
| Mohammed, A | 1 |
| Janakiram, NB | 1 |
| Li, Q | 1 |
| Ritchie, RL | 1 |
| Lightfoot, S | 1 |
| Vibhudutta, A | 1 |
| Steele, VE | 1 |
| White, AA | 1 |
| Stevenson, DD | 1 |
| Gu, DQ | 1 |
| Luo, B | 1 |
| Long, XA | 1 |
| Duan, CZ | 1 |
| Carlson, AP | 1 |
| Alaraj, A | 1 |
| Amin-Hanjani, S | 1 |
| Charbel, FT | 1 |
| Aletich, VA | 1 |
| Carlson, LM | 1 |
| Rasmuson, A | 1 |
| Idborg, H | 1 |
| Segerström, L | 1 |
| Jakobsson, PJ | 1 |
| Sveinbjörnsson, B | 1 |
| Kogner, P | 1 |
| de Boer, HC | 1 |
| van Solingen, C | 1 |
| Prins, J | 1 |
| Duijs, JM | 1 |
| Huisman, MV | 1 |
| Rabelink, TJ | 1 |
| van Zonneveld, AJ | 1 |
| Melnik, B | 1 |
| Hariry, H | 1 |
| Vakilzadeh, F | 1 |
| Gropp, C | 1 |
| Sitzer, G | 1 |
| Schrodi, J | 1 |
| Recio, L | 1 |
| Fiorellini, J | 1 |
| Howell, H | 1 |
| Goodson, M | 1 |
| Karimbux, N | 1 |
| Nogi, K | 1 |
| Taniguchi, H | 1 |
| Onoda, Y | 1 |
| Wong, KS | 2 |
| Liu, JY | 1 |
| Gao, S | 1 |
| Lam, WW | 2 |
| Sirima, SB | 1 |
| Konaté, A | 1 |
| Tiono, AB | 1 |
| Convelbo, N | 1 |
| Cousens, S | 1 |
| Pagnoni, F | 1 |
| Moyad, MA | 1 |
| Fan, YH | 1 |
| Zhang, L | 1 |
| Mok, VC | 1 |
| Jain, A | 1 |
| Sarraf, D | 1 |
| Fong, D | 1 |
| Rödén-Jüllig, A | 1 |
| Britton, M | 1 |
| Malmkvist, K | 1 |
| Leijd, B | 1 |
| Brune, K | 1 |
| Garber, K | 1 |
| Payne, DA | 1 |
| Jones, CI | 1 |
| Hayes, PD | 1 |
| Thompson, MM | 1 |
| London, NJ | 1 |
| Bell, PR | 1 |
| Goodall, AH | 1 |
| Naylor, AR | 1 |
| Cosin-Sales, J | 1 |
| Christiansen, M | 1 |
| Kaminski, P | 1 |
| Oxvig, C | 1 |
| Overgaard, MT | 1 |
| Cole, D | 1 |
| Holt, DW | 1 |
| Kaski, JC | 1 |
| Crovetto, M | 1 |
| Solano, D | 1 |
| Centeno, J | 1 |
| Scranton, R | 1 |
| Sesso, HD | 1 |
| Levenson, JW | 1 |
| Henkin, Y | 1 |
| Abuful, A | 1 |
| Yosefi, C | 1 |
| Elis, A | 1 |
| Ilia, R | 1 |
| Gidron, Y | 1 |
| Guzman-Cottrill, JA | 1 |
| Shulman, ST | 1 |
| Hwong, TM | 1 |
| Arifi, AA | 1 |
| Wan, IY | 1 |
| Thung, KH | 1 |
| Wan, S | 1 |
| Sung, RY | 1 |
| Yim, AP | 1 |
| Bell, NP | 1 |
| Orengo-Nania, S | 1 |
| Pietz, K | 1 |
| Gross, RL | 1 |
| Rioufol, G | 1 |
| Gilard, M | 1 |
| Finet, G | 1 |
| Ginon, I | 1 |
| Boschat, J | 1 |
| André-Fouët, X | 1 |
| Finazzi, G | 2 |
| Caruso, V | 1 |
| Marchioli, R | 2 |
| Capnist, G | 1 |
| Chisesi, T | 1 |
| Finelli, C | 1 |
| Gugliotta, L | 1 |
| Kutti, J | 1 |
| Gisslinger, H | 1 |
| Marilus, R | 1 |
| Patrono, C | 1 |
| Pogliani, EM | 1 |
| Randi, ML | 1 |
| Villegas, A | 1 |
| Tognoni, G | 2 |
| Lanthier, S | 1 |
| Armstrong, D | 1 |
| Domi, T | 1 |
| deVeber, G | 1 |
| Kwon, SU | 1 |
| Cho, YJ | 1 |
| Koo, JS | 1 |
| Hong, KS | 1 |
| Lee, JH | 1 |
| Baigent, C | 1 |
| Landray, M | 1 |
| Leaper, C | 1 |
| Altmann, P | 1 |
| Armitage, J | 1 |
| Baxter, A | 1 |
| Cairns, HS | 1 |
| Collins, R | 1 |
| Foley, RN | 1 |
| Frighi, V | 1 |
| Kourellias, K | 1 |
| Ratcliffe, PJ | 1 |
| Rogerson, M | 1 |
| Scoble, JE | 1 |
| Tomson, CR | 1 |
| Warwick, G | 1 |
| Wheeler, DC | 1 |
| Kawasaki, Y | 1 |
| Hosoya, M | 1 |
| Takahashi, A | 1 |
| Isome, M | 1 |
| Tanji, M | 1 |
| Suzuki, H | 1 |
| Krane, V | 1 |
| Wanner, C | 1 |
| Wingerchuk, DM | 1 |
| Benarroch, EE | 1 |
| O'Brien, PC | 1 |
| Keegan, BM | 1 |
| Lucchinetti, CF | 1 |
| Noseworthy, JH | 1 |
| Weinshenker, BG | 1 |
| Rodriguez, M | 1 |
| Ramaswami, G | 1 |
| D'Ayala, M | 1 |
| Hollier, LH | 1 |
| Deutsch, R | 1 |
| McElhinney, AJ | 1 |
| Phillips, DR | 1 |
| Conley, PB | 1 |
| Sinha, U | 1 |
| Andre, P | 1 |
| Toyoda, K | 1 |
| Minematsu, K | 1 |
| Kamouchi, M | 1 |
| Ibayashi, S | 1 |
| Cyrus, T | 1 |
| Yao, Y | 1 |
| Tung, LX | 1 |
| Praticò, D | 1 |
| Ruiz-Irastorza, G | 1 |
| Khamashta, MA | 1 |
| Ovbiagele, B | 1 |
| Lynn, MJ | 1 |
| Chimowitz, M | 1 |
| Poulsen, TS | 1 |
| Jørgensen, B | 1 |
| Korsholm, L | 1 |
| Licht, PB | 1 |
| Haghfelt, T | 1 |
| Mickley, H | 1 |
| Ishikawa, T | 1 |
| Mutoh, M | 1 |
| Fuda, Y | 1 |
| Sakamoto, H | 1 |
| Okada, H | 1 |
| Higashitani, M | 1 |
| Nakano, Y | 1 |
| Yamaguchi, J | 1 |
| Enta, K | 1 |
| Satoh, T | 1 |
| Imai, K | 2 |
| Horie, T | 1 |
| Mochizuki, S | 1 |
| Jug, B | 1 |
| Sebestjen, M | 1 |
| Sabovic, M | 1 |
| Keber, I | 1 |
| Di Nisio, M | 1 |
| Borrelli, G | 1 |
| Leone, G | 1 |
| Marfisi, R | 1 |
| Porreca, E | 1 |
| Rutjes, AW | 1 |
| Vannucchi, AM | 1 |
| Dieker, HJ | 1 |
| French, JK | 1 |
| Joziasse, IC | 1 |
| Brouwer, MA | 1 |
| Elliott, J | 1 |
| West, TM | 1 |
| Webber, BJ | 1 |
| Verheugt, FW | 1 |
| White, HD | 1 |
| McLachlan, CS | 1 |
| Zhang, Z | 2 |
| Mossop, P | 1 |
| Assy, N | 1 |
| Hussein, O | 1 |
| Khalil, A | 1 |
| Luder, A | 1 |
| Szvalb, S | 1 |
| Paizi, M | 1 |
| Spira, G | 1 |
| Jeon, HW | 1 |
| Cha, JK | 1 |
| Benninger, DH | 1 |
| Gandjour, J | 1 |
| Georgiadis, D | 1 |
| Stöckli, E | 1 |
| Arnold, M | 1 |
| Baumgartner, RW | 1 |
| Satish, B | 1 |
| Tressa, K | 1 |
| Harish, CR | 1 |
| Jonas, JB | 1 |
| De Castro, DK | 1 |
| Punjabi, OS | 1 |
| Bostrom, AG | 1 |
| Stamper, RL | 1 |
| Lietman, TM | 1 |
| Ray, K | 1 |
| Lin, SC | 1 |
| Schaeffner, ES | 1 |
| Kurth, T | 1 |
| Bowman, TS | 1 |
| Gelber, RP | 1 |
| Hereng, T | 1 |
| Lambert, M | 1 |
| Hachulla, E | 1 |
| Samor, M | 1 |
| Dubucquoi, S | 1 |
| Caron, C | 1 |
| Launay, D | 1 |
| Morell-Dubois, S | 1 |
| Queyrel, V | 1 |
| Hatron, PY | 1 |
| Schulz, C | 1 |
| Konrad, I | 1 |
| Sauer, S | 1 |
| Orschiedt, L | 1 |
| Koellnberger, M | 1 |
| Lorenz, R | 1 |
| Walter, U | 1 |
| Massberg, S | 1 |
| Kirichenko, AA | 1 |
| Mantserova, OA | 1 |
| Lebedeva, AIu | 1 |
| D'iachkova, NV | 1 |
| Voloshina, NM | 1 |
| Mazurov, VI | 1 |
| Nifontov, VM | 1 |
| Tyrenko, VV | 1 |
| Kolina, IG | 1 |
| Cherkashina, AL | 1 |
| Shkodina, NV | 1 |
| Mazalov, KV | 1 |
| Spiropulos, NA | 1 |
| Eremenko, IA | 1 |
| Kuzin, AI | 1 |
| Yee, J | 1 |
| Cimaz, R | 1 |
| Lega, JC | 1 |
| Mitsutake, R | 1 |
| Shirai, K | 1 |
| Nishikawa, H | 1 |
| Saito, N | 1 |
| Miura, S | 1 |
| Saku, K | 1 |
| Andreozzi, GM | 1 |
| Arosio, E | 1 |
| Martini, R | 1 |
| Verlato, F | 1 |
| Visonà, A | 1 |
| Sirois, C | 1 |
| Poirier, P | 1 |
| Moisan, J | 1 |
| Grégoire, JP | 1 |
| Flemmig, TF | 1 |
| Rumetsch, M | 1 |
| Klaiber, B | 1 |
| Fuster, V | 1 |
| Badimon, J | 1 |
| Chesebro, JH | 1 |
| Fallon, JT | 1 |
| Zelger, B | 1 |
| Brown, BG | 1 |
| Zhao, XQ | 1 |
| Bardsley, J | 1 |
| Albers, JJ | 1 |
| Shastri, GV | 1 |
| Thomas, M | 1 |
| Victoria, AJ | 1 |
| Selvakumar, R | 1 |
| Kanagasabapathy, AS | 1 |
| Thomas, K | 1 |
| Balsano, F | 1 |
| Tanaka, T | 1 |
| Takei, M | 1 |
| Fukuta, Y | 1 |
| Higashino, R | 1 |
| Fukuda, Y | 1 |
| Nomura, Y | 1 |
| Ito, S | 1 |
| Tamaki, H | 1 |
| Kurimoto, T | 1 |
| Suzuki, Y | 1 |
| Laurora, G | 1 |
| DeSanctis, MT | 1 |
| Incandela, L | 1 |
| Fugazza, L | 1 |
| Girardello, R | 1 |
| Poli, A | 1 |
| Peracino, L | 1 |
| Ambrosoli, L | 1 |
| Yamamoto, H | 1 |
| Itoh, F | 1 |
| Fukushima, H | 1 |
| Hinoda, Y | 1 |
| Dahlem, PG | 1 |
| von Rosenstiel, IA | 1 |
| Lam, J | 1 |
| Kuijpers, TW | 1 |
| Wilson, JM | 1 |
| Ferguson, JJ | 1 |
| Gu, Z | 1 |
| Qiu, W | 1 |
| He, R | 1 |
| Zhou, X | 1 |
| Benson, WE | 1 |
| Remaley, NA | 1 |
| Lindley, AA | 1 |
| Burton, TC | 1 |
| Csaky, K | 1 |
| Williams, GA | 1 |
| Ferris, FL | 1 |
| Silverstein, MN | 1 |
| Griesshammer, M | 1 |
| Bergmann, L | 1 |
| Pearson, T | 1 |
| Tektonidou, MG | 1 |
| Ioannidis, JP | 1 |
| Boki, KA | 1 |
| Vlachoyiannopoulos, PG | 1 |
| Moutsopoulos, HM | 1 |
| Toni, D | 1 |
| Argentino, C | 1 |
| Fieschi, C | 1 |
| Théroux, P | 1 |
| Alexander, J | 1 |
| Pharand, C | 1 |
| Barr, E | 1 |
| Snapinn, S | 1 |
| Ghannam, AF | 1 |
| Sax, FL | 1 |
| Riazanov, AS | 1 |
| Gabbasov, ZA | 1 |
| Iurenev, AP | 1 |
| Brière, J | 2 |
| Guilmin, F | 1 |
| Marotta, A | 1 |
| Tan, C | 1 |
| Gray, V | 1 |
| Malik, S | 1 |
| Gallinger, S | 1 |
| Sanghera, J | 1 |
| Dupuis, B | 1 |
| Owen, D | 1 |
| Dedhar, S | 1 |
| Salh, B | 1 |
| Kwek, K | 1 |
| Yeo, GS | 1 |
| Makino, H | 1 |
| Tanaka, I | 1 |
| Mukoyama, M | 1 |
| Sugawara, A | 1 |
| Mori, K | 1 |
| Muro, S | 1 |
| Suganami, T | 1 |
| Yahata, K | 1 |
| Ishibashi, R | 1 |
| Ohuchida, S | 1 |
| Maruyama, T | 1 |
| Narumiya, S | 1 |
| Nakao, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy[NCT05525156] | Phase 2 | 454 participants (Anticipated) | Interventional | 2020-03-02 | Suspended (stopped due to The study stopped due to expiry of study drugs) | ||
| Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial[NCT04324463] | Phase 3 | 6,667 participants (Actual) | Interventional | 2020-04-21 | Active, not recruiting | ||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Effect of Aspirin on Renal Disease Progression in Patients With Type 2 Diabetes: a Multicentre Double-blind, Placebo-controlled, Randomised Trial. The LEDA (renaL disEase Progression by Aspirin in Diabetic pAtients) Study.[NCT02895113] | Phase 3 | 418 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
| Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)[NCT01709994] | Phase 3 | 97 participants (Anticipated) | Interventional | 2010-05-31 | Recruiting | ||
| A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia[NCT00175838] | 1,398 participants (Actual) | Interventional | 1997-07-31 | Completed | |||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Diseas[NCT01877915] | Phase 3 | 5,081 participants (Actual) | Interventional | 2013-09-10 | Completed | ||
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Aspirin (Acetylsalicylic Acid) in the Prevention of Collapse of the Femoral Head in Early-stage Non-traumatic Osteonecrosis: a Two-year Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study[NCT03405974] | Phase 3 | 114 participants (Anticipated) | Interventional | 2017-10-12 | Recruiting | ||
| A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory[NCT00238238] | Phase 2 | 97 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System（G-stream） in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359] | 280 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | |||
| Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406] | 474 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk[NCT02394769] | 180 participants (Actual) | Interventional | 2015-07-06 | Active, not recruiting | |||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Investigation of Relevant Biomarkers in Patients With Susac Syndrome[NCT01273792] | 30 participants (Anticipated) | Observational | 2010-05-31 | Recruiting | |||
| Effect of Conditioning on Myocardial Damage in ST-elevation Myocardial Infarction - Comparison of Combined Intrahospital Preconditioning Plus Postconditioning Versus Postconditioning Versus Control.[NCT02158468] | 600 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Postconditioning Used to Limit Final Infarct Size in Patients With Acute ST-segment Elevation Myocardial Infarction[NCT00507156] | Phase 4 | 200 participants (Anticipated) | Interventional | 2007-07-31 | Completed | ||
| Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. Clinical Trial of Low Level of Intervention. (Ineox Study)[NCT03328845] | Phase 4 | 300 participants (Actual) | Interventional | 2017-01-20 | Completed | ||
| Is a Reduced Biochemical Response to Aspirin Associated With Increased Cardiovascular Morbidity and Mortality in High Risk Patients With Coronary Artery Disease?[NCT01383304] | 906 participants (Actual) | Observational | 2007-11-30 | Active, not recruiting | |||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial[NCT00202020] | Phase 3 | 720 participants | Interventional | 2004-05-31 | Completed | ||
| the Treatment of Intracranial Aneurysm Using Different Types of Stents Assisted Embolization :Trials of Clinical Curative Effect, Follow-up Study and Hemodynamics[NCT03387995] | 2,000 participants (Anticipated) | Observational | 2016-09-01 | Active, not recruiting | |||
| Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy[NCT00287651] | Phase 2/Phase 3 | 150 participants (Actual) | Interventional | 2005-11-30 | Terminated (stopped due to Administrative) | ||
| Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease[NCT00755677] | Early Phase 1 | 26 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound[NCT01200056] | Phase 4 | 40 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Focal Cerebral Arteriopathy Steroid Trial[NCT06040255] | Phase 4 | 80 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial[NCT00125593] | Phase 4 | 9,438 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Randomized Clinical Trial of Intravitreal dexamethasOne Versus Bevacizumab in Aboriginal and Torres Strait Islander patientS With Diabetic Macular Oedema (The OASIS Study)[NCT04619303] | Phase 4 | 59 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 24.84 |
| Placebo | 24.57 |
Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.44 |
| Placebo | 14.27 |
Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 1.52 |
| Placebo | 1.16 |
Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 9.46 |
| Placebo | 9.96 |
Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 23.32 |
| Placebo | 23.46 |
Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 2.04 |
| Placebo | 1.21 |
Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.30 |
| Placebo | 14.04 |
Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 17.24 |
| Placebo | 17.45 |
Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) | |
|---|---|---|
| Fatal Bleeding | Critical Space Bleeding with Permanent Disability | |
| Placebo | 0.22 | 0.48 |
| Rivaroxaban | 0.22 | 0.32 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
Response is assessed by investigator according to International Working Group (IWG) criteria. A complete response requires disappearance of all evidence of disease. A partial response is a >/= 50% decrease in the sum of products of 6 largest dominant nodes or nodal masses as well as for splenic and hepatic nodules. No increase in size of nodes, liver or spleen and no new sites of disease. (NCT00238238)
Timeframe: Duration of treatment (12 cycles)
| Intervention | percentage of participants (Number) |
|---|---|
| Arm II - Lenalidomide | 53.3 |
| Arm III - Lenalidomide and Rituximab | 76.1 |
Time to progression (TTP) is defined as the time from study entry until progression or death without progression. The median TTP with 95% CI was estimated using the Kaplan-Meier method. (NCT00238238)
Timeframe: Up to 10 years
| Intervention | years (Median) |
|---|---|
| Arm II - Lenalidomide | 1.1 |
| Arm III - Lenalidomide and Rituximab | 2 |
"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 90.4 |
| PTA (Control) | 83.9 |
Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 82.7 |
| PTA (Control) | 32.7 |
Measured using liquid chromatography/mass spectrometry (NCT02394769)
Timeframe: 8-12 weeks
| Intervention | ng/mg cr (Mean) | ||
|---|---|---|---|
| Baseline urinary PGE-M | Post-intervention urinary PGE-M | Change in urinary PGE-M | |
| Low Dose Aspirin | 17.7 | 13.1 | -4.6 |
| Placebo (For Aspirin) | 15.5 | 16.4 | 0.8 |
| Standard Dose Aspirin | 14.3 | 9.4 | -4.9 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
Revascularization included any arterial revascularization procedure, whether surgical or percutaneous, but excluded revascularization performed for hemodialysis vascular access (e.g. fistuloplasty) or to the donor kidney transplant artery. Revascularization included amputations for vascular disease (rather than for trauma or infection). All potential revascularization events (including angiography) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 284 |
| Placebo | 352 |
End-stage renal disease was defined as initiation of maintenance dialysis or renal transplantation. Temporary dialysis was excluded. All potential dialysis and transplant events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 1057 |
| Placebo | 1084 |
Major atherosclerotic events defined as non-fatal myocardial infarction or coronary death, non-hemorrhagic stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 526 |
| Placebo | 619 |
Major coronary events defined as coronary death or non-fatal myocardial infarction. Myocardial infarction adjudicated based on the presence of serial changes in cardiac biomarkers (e.g. troponin, creatine kinase), typical ECG changes and typical cardiac symptoms. If myocardial infarction was fatal and post-mortem examination findings were available, this information was also assessed. All potential coronary events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 213 |
| Placebo | 230 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 701 |
| Placebo | 814 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 639 |
| Placebo | 749 |
Stroke was defined as rapid onset of focal or global neurological deficit, with duration greater than 24 hours. Clinical notes and brain imaging were sought to determine the stroke etiology, and if the stroke was fatal and post-mortem examination findings were available, this information was also assessed. All potential stroke events (including transient ischemic attack and intracerebral hemorrhage) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 131 |
| Placebo | 174 |
56 reviews available for aspirin and Disease Exacerbation
| Article | Year |
|---|---|
Cardiovascular Outcomes in Systemic Lupus Erythematosus.
Topics: Aspirin; Cardiovascular Diseases; Disease Progression; Humans; Inflammation; Lupus Erythematosus, Sy | 2022 |
Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Chronic Disease; Coronary Artery Dis | 2019 |
A systematic review and meta-analysis of traumatic intracranial hemorrhage in patients taking prehospital antiplatelet therapy: Is there a role for platelet transfusions?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Disease Progression; Humans; Intracranial Hemorrhage, | 2020 |
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Aspirin; Biological Products; Breast | 2020 |
Pregnancy and cardiovascular disease.
Topics: Acute Coronary Syndrome; Antihypertensive Agents; Aortic Dissection; Arrhythmias, Cardiac; Aspirin; | 2020 |
Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy.
Topics: Aspirin; Blood Platelets; Disease Progression; Elastin; Electron Transport; Humans; Inflammation; Lu | 2020 |
The role of aspirin in the primary prevention of accelerated atherosclerosis in systemic autoimmune rheumatic diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Autoimmune Diseases; Disease Prog | 2020 |
The multiple effects of aspirin in prostate cancer patients.
Topics: Aspirin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; D | 2021 |
Aspirin in people with dementia, long-term benefits, and harms: a systematic review.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardio | 2021 |
Aspirin exacerbated respiratory disease (AERD): molecular and cellular diagnostic & prognostic approaches.
Topics: Animals; Aspirin; Disease Progression; Genetic Predisposition to Disease; Humans; Polymorphism, Gene | 2021 |
Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, | 2021 |
Tuberculous and Infectious Pericarditis.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal | 2017 |
Approaches and techniques to avoid development or progression of acute respiratory distress syndrome.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Critical Care | 2018 |
Aspirin exacerbated respiratory disease: Current topics and trends.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arachidonic Acid; Aspirin; A | 2018 |
Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Comorbidity; Disease Management; Disease Progression; | 2018 |
Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
Topics: Aspirin; Cardiovascular Diseases; Disease Progression; Fibrinolytic Agents; Humans; Peripheral Arter | 2013 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
Identifying asthma triggers.
Topics: Allergens; Aspirin; Asthma; Disease Progression; Female; Gastroesophageal Reflux; Humans; Male; Prog | 2014 |
Systematic study of cilostazol on secondary stroke prevention: a meta-analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Disease Progression; Humans; Incidenc | 2013 |
NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocation Tests; Disease Progr | 2015 |
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
Topics: Aspirin; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Hydroxyurea; Incid | 2015 |
Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Topics: Aspirin; Diagnosis, Differential; Disease Management; Disease Progression; Humans; Janus Kinase 2; P | 2015 |
Pregnancy and Lupus Nephritis.
Topics: Abortion, Spontaneous; Anticoagulants; Antihypertensive Agents; Antiphospholipid Syndrome; Aspirin; | 2015 |
Chemoprevention of colorectal neoplasia.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, No | 2017 |
Pregnancy in women with systemic lupus erythematosus (SLE).
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspi | 2016 |
Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Disease Progres | 2016 |
Chronic Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease.
Topics: Allergens; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Disease Progre | 2016 |
Does the use of acetylsalicylic acid have an influence on our vision?
Topics: Aspirin; Disease Progression; Humans; Macular Degeneration; Retinal Pigment Epithelium; Visual Acuit | 2016 |
Pharmacotherapy of essential thrombocythemia.
Topics: Age Factors; Antineoplastic Agents; Aspirin; Disease Progression; Humans; Hydroxyurea; Interferon-al | 2008 |
Rapid desensitization for hypersensitivity reactions to medications.
Topics: Anaphylaxis; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2009 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu | 2009 |
Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Disease Progression; Dose-Respo | 2010 |
Polycythemia vera.
Topics: Aspirin; Disease Progression; Fibrinolytic Agents; Humans; Janus Kinase 2; Mutation; Phlebotomy; Pol | 2010 |
[What's new in recurrent pericarditis in 2011?].
Topics: Acute Disease; Algorithms; Aspirin; Colchicine; Disease Progression; Humans; Pericarditis; Recurrenc | 2011 |
Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Aspirin; Brain; Diagnosis, Differential; D | 2011 |
Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus.
Topics: Aspirin; Atherosclerosis; Biomarkers; Calcium; Coronary Vessels; Diabetic Angiopathies; Disease Prog | 2011 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
Clinical review: Early treatment of acute lung injury--paradigm shift toward prevention and treatment prior to respiratory failure.
Topics: Acute Lung Injury; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Anti-Inflammatory A | 2012 |
Anti-platelet treatment of middle-sized abdominal aortic aneurysms.
Topics: Animals; Aortic Aneurysm, Abdominal; Aspirin; Clinical Trials as Topic; Disease Models, Animal; Dise | 2013 |
Pharmacological prevention and treatment of vascular dementia: approaches and perspectives.
Topics: Alzheimer Disease; Antihypertensive Agents; Aspirin; Cholinesterase Inhibitors; Cognition; Dementia, | 2012 |
Case report of subdural hematoma in a patient with Sturge-Weber syndrome and literature review: questions and implications for therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrophy; Brain; Child, Preschool; Developmental Di | 2013 |
Cancer prevention by targeting angiogenesis.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; | 2012 |
Safety of anti-inflammatory treatment--new ways of thinking.
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cycl | 2004 |
Recent developments and controversies in Kawasaki disease.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Dru | 2004 |
Post-varicella arteriopathy of childhood: natural history of vascular stenosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiog | 2005 |
Therapeutic approaches in arterial thrombosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atherosclerosis; Blood Pl | 2005 |
[Systematic lupus erythematosus and antiphospholipid syndrome during pregnancy].
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Disease Progression; Female; Humans; Immunosuppr | 2006 |
The benefit of aspirin therapy in type 2 diabetes: what is the evidence?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progres | 2008 |
Plaque rupture, thrombosis, and therapeutic implications.
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Coronary Thrombosis; Disease Pr | 1996 |
Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States.
Topics: Aspirin; Cardiology; Coronary Angiography; Coronary Disease; Disease Progression; Humans; Lipids; My | 1997 |
Rationale for the use of antiplatelet drugs in patients with peripheral vascular disease.
Topics: Arteriosclerosis; Aspirin; Clinical Trials as Topic; Disease Progression; Humans; Intermittent Claud | 1994 |
Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications.
Topics: Animals; Arteriosclerosis; Aspirin; Disease Progression; Endothelium, Vascular; Humans; Platelet Act | 1999 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Fertility, pregnancy and the management of myeloproliferative disorders.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Alkylating Agents; Animals; Aspirin; Bone Marrow | 1998 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr | 2001 |
Current understanding of pre-eclampsia.
Topics: Anticoagulants; Aspirin; Biomarkers; Delivery, Obstetric; Disease Progression; Female; Humans; Mass | 2002 |
46 trials available for aspirin and Disease Exacerbation
| Article | Year |
|---|---|
Effect of aspirin on HIV disease progression among HIV-infected individuals initiating antiretroviral therapy: study protocol for a randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Aspirin; CD4 Lymphocyte Count; Disease Progression; HIV Infections; H | 2021 |
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.
Topics: Aspirin; Canada; Colchicine; COVID-19; Disease Progression; Humans; SARS-CoV-2; Thrombosis; Treatmen | 2022 |
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.
Topics: Adolescent; Adult; Aspirin; Canada; Colchicine; COVID-19 Drug Treatment; Disease Progression; Humans | 2022 |
In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d.
Topics: Aspirin; Colchicine; COVID-19; Disease Progression; Humans; Outpatients; Treatment Outcome | 2023 |
Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design.
Topics: Aspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus, Type 2; Disease Progression; Dose-Response Re | 2017 |
Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Disease Progression; Female; Glomerul | 2018 |
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
Topics: Adult; Aspirin; Australia; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio | 2018 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Carotid Intima-Media Thickness; Cilostazol | 2019 |
The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dis | 2019 |
Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke.
Topics: Aged; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Protein; Cilostazol; Disease Progression; Doub | 2014 |
Treatment with acetylsalicylic acid prevents short to mid-term radiographic progression of nontraumatic osteonecrosis of the femoral head: a pilot study.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progres | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Slowing the progression of age-related hearing loss: Rationale and study design of the ASPIRIN in HEARING, retinal vessels imaging and neurocognition in older generations (ASPREE-HEARING) trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Audiometry, Pure-Tone; Au | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method | 2016 |
Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
Topics: Adolescent; Adult; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Disease Progression; Dou | 2016 |
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Aspirin; Biomarkers, T | 2017 |
Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Aspirin; Boston; Disease Progression; Human | 2017 |
Association of renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study.
Topics: Angiotensinogen; Antioxidants; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Progressi | 2008 |
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
Topics: Adult; Aged; Antioxidants; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic A | 2008 |
Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Aspirin; Cerebrovascular Disorders; Cost-Benefi | 2009 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Disease | 2010 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona | 2011 |
Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial.
Topics: Anticoagulants; Aspirin; Cohort Studies; Disease Progression; Enoxaparin; Female; Follow-Up Studies; | 2011 |
Comparing virtual with conventional microscopy for the consensus diagnosis of Barrett's neoplasia in the AspECT Barrett's chemoprevention trial pathology audit.
Topics: Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Disease Progression; Esomeprazole; Esophageal Neoplas | 2012 |
Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2012 |
Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions.
Topics: Aspirin; Blood Pressure; Brain; Brain Diseases; Cerebral Hemorrhage; Cilostazol; Disease Progression | 2012 |
The effect of aspirin on the periodontal parameter bleeding on probing.
Topics: Adult; Analysis of Variance; Aspirin; Dental Plaque Index; Disease Progression; Double-Blind Method; | 2002 |
Aspirin in the prevention of progressing stroke: a randomized controlled study.
Topics: Acute Disease; Aged; Aspirin; Disease Progression; Double-Blind Method; Female; Fibrinolytic Agents; | 2003 |
Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Progression; Drug Therapy, Combination; Endar | 2004 |
Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Body Weight; Cholesterol; | 2004 |
Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis.
Topics: Aged; Angiography; Arteries; Aspirin; Brain; Cilostazol; Constriction, Pathologic; Disease Progressi | 2005 |
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disea | 2005 |
A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.
Topics: Administration, Oral; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Ov | 2005 |
Rapid foot and calf compression increases walking distance in patients with intermittent claudication: results of a randomized study.
Topics: Administration, Oral; Aged; Aspirin; Disease Progression; Exercise Test; Follow-Up Studies; Humans; | 2005 |
Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Drug Resistance; Female | 2007 |
Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Output, Low; Clopidogrel; Cross-Over Studies; Disease Prog | 2006 |
Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Dipyridamole; Disease Progression; Drug Therapy, Co | 2007 |
Blood pressure measures and risk of chronic kidney disease in men.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Blood Pressure; Blood | 2008 |
[Unstable angina: efficacy and tolerability of therapy with aspirin and aspirin combined with ticlopidine].
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Drug Therap | 2007 |
Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase-alpha 1-proteinase inhibitor in gingival crevicular fluid.
Topics: Administration, Oral; Adult; Aged; alpha 1-Antitrypsin; Analysis of Variance; Anti-Inflammatory Agen | 1996 |
Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Arteriosclerosis; Aspirin; Carotid Artery D | 1999 |
Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25.
Topics: Aspirin; Cataract; Cataract Extraction; Diabetic Retinopathy; Disease Progression; Female; Humans; L | 1999 |
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Uns
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Diabetes Complications; Disease Progression; Double | 2000 |
153 other studies available for aspirin and Disease Exacerbation
| Article | Year |
|---|---|
Antiplatelet Medications and Biomarkers of Hemostasis May Explain the Association of Hematoma Appearance and Subsequent Hematoma Expansion After Intracerebral Hemorrhage.
Topics: Aspirin; Biomarkers; Cerebral Hemorrhage; Clopidogrel; Disease Progression; Hematoma; Hemostasis; Hu | 2022 |
FM0807 decelerates experimental arthritis progression by inhibiting inflammatory responses and joint destruction via modulating NF-κB and MAPK pathways.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Curcumin; Disease Progression; | 2019 |
Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Disease Progression; F | 2019 |
Risk stratification of non-obstructive coronary artery disease for guidance of preventive medical therapy.
Topics: Aged; Aspirin; Clinical Decision-Making; Computed Tomography Angiography; Coronary Angiography; Coro | 2019 |
Delayed progression of atherosclerosis and cardiovascular events in asymptomatic patients with atherosclerotic plaques: 3-year prevention with the supplementation with Pycnogenol®+Centellicum®.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Centella; D | 2020 |
Central cardiovascular calcifications: supplementation with Pycnogenol® and Centellicum®: variations over 12 months.
Topics: Aspirin; Cardiovascular Diseases; Centella; Coronary Artery Disease; Dietary Supplements; Disease Ma | 2020 |
Daily Aspirin Use Associated With Reduced Risk for Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease.
Topics: Aspirin; Disease Progression; Fibrosis; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2020 |
Anticoagulant and anti-thrombotic therapy in acute type B aortic dissection: when real-life scenarios face the shadows of the evidence-based medicine.
Topics: Anticoagulants; Aortic Aneurysm, Thoracic; Aortic Dissection; Aspirin; Clinical Decision-Making; Clo | 2020 |
Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit | 2020 |
Unexpected effects of long-term treatment with acetylsalicylic acid on late phase of pulmonary metastasis in murine model of orthotopic breast cancer.
Topics: Animals; Aspirin; Breast Neoplasms; Disease Models, Animal; Disease Progression; Female; Lung Neopla | 2020 |
[Is Concomitant Therapy with Acetaminophen and Low-dose Aspirin a Risk Factor for CKD Progression? A 6-Year Cohort Study].
Topics: Acetaminophen; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Biomarkers; Creatinine; Diabete | 2020 |
Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis.
Topics: Aged; Aspirin; Cilostazol; Disease Progression; Dual Anti-Platelet Therapy; Female; Humans; Japan; M | 2021 |
Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia.
Topics: Animals; Aspirin; Chemoprevention; Cholecystolithiasis; Cholesterol; Cholesterol, Dietary; Chronic D | 2020 |
Rabbit Elastase Aneurysm: Imaging and Histology Correlates for Inflammation and Healing.
Topics: Animals; Aspirin; Carotid Artery Diseases; Carotid Artery, Common; Disease Models, Animal; Disease P | 2021 |
Platelet Reactivity Testing for Aspirin Patients Who Sustain Traumatic Intracranial Hemorrhage.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Disease Progression; Female; Humans; Intr | 2021 |
Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?
Topics: Aspirin; Atherosclerosis; Blood Platelets; Disease Progression; Dose-Response Relationship, Drug; Dr | 2021 |
Epithelial dysregulation in chronic rhinosinusitis with nasal polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD).
Topics: Aspirin; Biomarkers; Chronic Disease; Disease Progression; Disease Susceptibility; Humans; Nasal Pol | 2021 |
Outcomes of a single-center experience with classification and treatment of endothermal heat-induced thrombosis after endovenous ablation.
Topics: Anticoagulants; Aspirin; Catheter Ablation; Disease Progression; Endovascular Procedures; Female; Ho | 2017 |
Assessment of 'on-treatment platelet reactivity' and relationship with cerebral micro-embolic signals in asymptomatic and symptomatic carotid stenosis.
Topics: Aged; Aspirin; Brain; Carotid Stenosis; Case-Control Studies; Clopidogrel; Disease Progression; Fema | 2017 |
Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotein I; Cells, Cult | 2018 |
Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.
Topics: Adrenergic beta-Antagonists; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Anti-Infl | 2018 |
Alzheimer's Disease Progression: Factors Influencing Cognitive Decline.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoprotein E4; Aspirin; Cognitive Dysfuncti | 2018 |
A Longitudinal Cohort Study of Aspirin Use and Progression of Emphysema-like Lung Characteristics on CT Imaging: The MESA Lung Study.
Topics: Aged; Aged, 80 and over; Aspirin; Cyclooxygenase Inhibitors; Disease Progression; Dose-Response Rela | 2018 |
Aspirin does not prevent growth of vestibular schwannomas: A case-control study.
Topics: Aged; Aspirin; Case-Control Studies; Cyclooxygenase Inhibitors; Disease Progression; Female; Humans; | 2018 |
Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Cerebral Infarction; Chi-Square Distribution; Cilostaz | 2018 |
The association of aspirin use with severity of acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progressio | 2018 |
Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinogenesis; Carcinom | 2018 |
Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Disease Progression; Female; Humans; Male; Myocard | 2018 |
Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Diet, High-Fat; Disease Models, Animal; Disease Progres | 2018 |
Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; China; Clinical Decision-Making; Clopidogrel; Cyto | 2018 |
Targeting Cardiovascular Disease in Patients with Chronic Kidney Disease: Is Primary Prevention with Aspirin Ready for Prime Time? : Editorial to: "Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Di
Topics: Aspirin; Cardiovascular Diseases; Disease Progression; Humans; Primary Prevention; Renal Insufficien | 2018 |
Aspirin desensitization in aspirin-exacerbated respiratory disease: New insights into the molecular mechanisms.
Topics: Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Cytokines; Desensitization, Immunologic; Disease Prog | 2018 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Are Prior Aspirin Users With ST-Elevation Myocardial Infarction at Increased Risk of Adverse Events and Worse Angiographic Features?
Topics: Aspirin; Coronary Angiography; Disease Progression; Female; Follow-Up Studies; Humans; Iran; Male; M | 2018 |
Hypothesis: Presymptomatic treatment of Sturge-Weber Syndrome With Aspirin and Antiepileptic Drugs May Delay Seizure Onset.
Topics: Anticonvulsants; Aspirin; Disease Progression; Humans; Infant; Platelet Aggregation Inhibitors; Seiz | 2019 |
Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study.
Topics: Adult; Aged; Aspirin; Disease Progression; Follow-Up Studies; Health Personnel; Humans; Male; Middle | 2019 |
Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Aspirin; Cohort Studies; Disease Progression; Duration of | 2019 |
Daily Aspirin Use Reduces Risk of Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease, Providing New Uses for an Old Drug.
Topics: Aspirin; Disease Progression; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2019 |
Reply.
Topics: Aspirin; Disease Progression; Fibrosis; Humans; Non-alcoholic Fatty Liver Disease | 2020 |
Effects of aspirin on cancer initiation and progression.
Topics: Antineoplastic Agents; Aspirin; Cyclooxygenase 2 Inhibitors; Disease Progression; Humans; Male; Neop | 2013 |
The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Anticoagulants; Aspirin; BCG Vaccine; Clopidogrel; | 2013 |
Progression of asymptomatic carotid stenosis despite optimal medical therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Asymptomatic Diseases; Biomarkers; Cardiovascular Agents; Carotid | 2013 |
Early and late mortality of spontaneous hemorrhagic transformation of ischemic stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Cohort Studies; Disease Progressio | 2014 |
Cutaneous involvement by post-polycythemia vera myelofibrosis.
Topics: Aged; Aspirin; Biopsy; Cell Lineage; Disease Progression; Drug Therapy, Combination; Fibrosis; Hemat | 2014 |
A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemot | 2013 |
Repeat head computed tomography in anticoagulated traumatic brain injury patients: still warranted.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Injuries; Clopidogrel; Cohort Studies | 2014 |
Impact of vitamin D deficiency upon clinical presentation in nasal polyposis.
Topics: Age Factors; Allergens; Antigens, Fungal; Aspirin; Black or African American; Cholecalciferol; Chron | 2014 |
Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1.
Topics: Administration, Oral; Angiopoietin-1; Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Ex | 2014 |
[Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; But | 2014 |
Childhood Cogan syndrome with aortitis and anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.
Topics: Adolescent; Adult; Antibodies, Antineutrophil Cytoplasmic; Antirheumatic Agents; Aortitis; Aspirin; | 2014 |
The natural history of asymptomatic severe carotid artery stenosis.
Topics: Aged; Aspirin; Asymptomatic Diseases; Blood Flow Velocity; Cardiovascular Agents; Carotid Stenosis; | 2014 |
Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Bronchial Pr | 2014 |
Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation.
Topics: Aspirin; Disease Progression; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplan | 2014 |
[Special characteristics of progression of myocardial remodeling in patients with various forms of unstable angina].
Topics: Aged; Angina, Unstable; Aspirin; Benzopyrans; Cardiovascular Agents; Disease Progression; Drug Thera | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Disease Progression; Health Res | 2014 |
Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2015 |
Challenge-proven aspirin hypersensitivity in children with chronic spontaneous urticaria.
Topics: Adolescent; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Chronic Disease; Co | 2015 |
Impact of Diagnostic Delay and Other Risk Factors on Eosinophilic Esophagitis Phenotype and Esophageal Diameter.
Topics: Adult; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; | 2016 |
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Creatinine; Disease Progression; Fema | 2015 |
Accuracy of optical frequency domain imaging for evaluation of coronary adventitial vasa vasorum formation after stent implantation in pigs and humans - a validation study - .
Topics: Adventitia; Aged; Aged, 80 and over; Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vess | 2015 |
[Kasabach-Merritt phenomenon (KMP) exacerbated by platelet transfusions].
Topics: Aspirin; Axilla; Combined Modality Therapy; Compression Bandages; Disease Progression; Disseminated | 2015 |
Sodium Cromoglycate Prevents Exacerbation of IgE-Mediated Food-Allergic Reaction Induced by Aspirin in a Rat Model of Egg Allergy.
Topics: Administration, Oral; Allergens; Anaphylaxis; Animals; Aspirin; Cromolyn Sodium; Disease Models, Ani | 2015 |
Elevated levels of antibodies against phosphatidylserine/prothrombin complex and/or cardiolipin associated with infection and recurrent purpura in a child: a forme fruste of antiphospholipid syndrome?
Topics: Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Autoantibodies; Bacterial Infection | 2015 |
[Acute unilateral arteritic anterior ischemic optic neuropathy becoming bilateral despite corticosteroid therapy].
Topics: Acute Disease; Aged; Alzheimer Disease; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Disease P | 2016 |
Altered expression and signalling of EP2 receptor in nasal polyps of AERD patients: role in inflammation and remodelling.
Topics: Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Proliferation; Cyclic AMP; Dinop | 2016 |
Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Aspirin; Carcinoma, Hepatocellular; Cathet | 2015 |
Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer.
Topics: Aged; Aspirin; Biliary Tract Neoplasms; Cardiovascular Agents; Comorbidity; Disease Progression; Dis | 2015 |
Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2017 |
Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Caspase 3; Cel | 2016 |
To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cardiovascular Agents; Disability Evaluation; Dise | 2016 |
Low-dose aspirin and rupture of abdominal aortic aneurysm.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Aortic Rupture; Aspirin; Case-Control Studies; | 2017 |
Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspi | 2016 |
CHARISMA revisited: is the glass half full or just empty?
Topics: Aspirin; Clopidogrel; Coronary Disease; Disease Progression; Humans; Platelet Aggregation Inhibitors | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Dietary aspirin decreases the stage of ovarian cancer in the hen.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chickens; Diet; Dinoprostone; Disease Mod | 2009 |
Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.
Topics: Administration, Intravesical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2009 |
Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats.
Topics: Animals; Aspirin; Blood Glucose; Body Weight; Carnosine; Cataract; Cornea; Diabetes Mellitus, Experi | 2008 |
Hearing loss in a woman on aspirin: the silent pharmacokinetic parameter.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Female; Hearing Loss; | 2009 |
Giant cell arteritis revealed by vertebrobasilar insufficiency.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Biopsy; Brain Stem Infarctions; Disease Progression; Fatal | 2009 |
Familial chilblain lupus--a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1.
Topics: Adolescent; Aspirin; Biopsy, Needle; Chronic Disease; Disease Progression; Drug Therapy, Combination | 2009 |
Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study.
Topics: Adolescent; Adult; Aged; Analgesics; Aspirin; Caffeine; Chronic Disease; Disease Progression; Female | 2010 |
Reduced platelet activity is associated with more intraventricular hemorrhage.
Topics: Adult; Aged; Aspirin; Blood Platelet Disorders; Blood Platelets; Cerebral Hemorrhage; Clopidogrel; C | 2009 |
The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
Topics: Amylases; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticarcinogenic Agents; Aspirin; Carci | 2010 |
Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Bip | 2010 |
Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome.
Topics: Aspirin; Auditory Perceptual Disorders; Brain; Cerebral Angiography; Diagnosis, Differential; Diseas | 2009 |
Diagnosis of aspirin-induced asthma combining the bronchial and the oral challenge tests: a pilot study.
Topics: Administration, Oral; Adult; Allergens; Aspirin; Asthma, Aspirin-Induced; Bronchial Provocation Test | 2009 |
Ultrasound evaluation of early changes in arterial dissection.
Topics: Aspirin; Blood Proteins; Carotid Artery, Internal; Carotid Artery, Internal, Dissection; Cerebrovasc | 2010 |
Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Algorithms; Anticarcinogenic Agents; Aspirin; Calibration; Cost-Benefit Analy | 2010 |
Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Topics: Adult; Aged; Aged, 80 and over; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular | 2010 |
Analgesic use and the risk for progression of chronic kidney disease.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin | 2010 |
Treatment outcome in a cohort of young patients with polycythemia vera.
Topics: Adult; Antineoplastic Agents; Aspirin; Cohort Studies; Combined Modality Therapy; Disease Progressio | 2010 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Pr | 2011 |
Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity.
Topics: Adult; Aged; Aspirin; Biomarkers, Tumor; Disease Progression; Follow-Up Studies; Humans; Kallikreins | 2012 |
Chemoprevention: First line of defence.
Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I | 2011 |
Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction.
Topics: Aged; Aspirin; Coronary Artery Disease; Disease Progression; Drug Resistance; Female; Humans; Male; | 2012 |
The effect of antiplatelet therapy in patients with inflammatory bowel disease.
Topics: Aspirin; Clopidogrel; Disease Progression; Female; Humans; Inflammatory Bowel Diseases; Male; Platel | 2012 |
[Cerebrovascular accident with haemorrhagic transformation in a patient on antiplatelet treatment subjected to surgery of a hypophyseal macroadenoma].
Topics: Adenoma; Aphasia, Broca; Aspirin; Cerebellum; Cerebral Hemorrhage; Craniotomy; Disease Progression; | 2012 |
Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.
Topics: Animals; Anticarcinogenic Agents; Aspirin; beta Catenin; Body Weight; Carcinoma in Situ; Carcinoma, | 2012 |
Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2012 |
The effect of Neuroform stent-assisted coil embolization of wide-necked intracranial aneurysms and clinical factors on progressive aneurysm occlusion on angiographic follow-up.
Topics: Adult; Aspirin; Cerebral Angiography; Clopidogrel; Disease Progression; Embolization, Therapeutic; F | 2013 |
Continued concern about parent vessel steno-occlusive progression with Onyx HD-500 and the utility of quantitative magnetic resonance imaging in serial assessment.
Topics: Angioplasty; Aspirin; Carotid Artery Diseases; Carotid Stenosis; Clopidogrel; Constriction, Patholog | 2013 |
Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma.
Topics: Animals; Aspirin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Dendritic Cells | 2013 |
Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease.
Topics: Analysis of Variance; Arachidonic Acid; Aspirin; Biomarkers; Contraindications; Diabetes Mellitus, T | 2013 |
[Malignant atrophic papulosis (Köhlmeier-Degos disease). Failure to respond to interferon alpha-2a, pentoxifylline and aspirin].
Topics: Aspirin; Atrophy; Connective Tissue; Diagnosis, Differential; Disease Progression; Drug Therapy, Com | 2002 |
Effects of the anti-ulcer agents ecabet sodium, cimetidine and sucralfate on acetylsalicylic acid-induced gastric mucosal damage deteriorated by renal failure in rats.
Topics: Abietanes; Acute Kidney Injury; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Disease Progression; Female; Hemoside | 2003 |
Early treatment of childhood fevers with pre-packaged antimalarial drugs in the home reduces severe malaria morbidity in Burkina Faso.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Aspirin; Burkina Faso; Child, Preschool; Chl | 2003 |
The use of complementary/preventive medicine to prevent prostate cancer recurrence/progression following definitive therapy. Part II--rapid review of dietary supplements.
Topics: Aspirin; Dietary Supplements; Disease Progression; Humans; Male; Prostatic Neoplasms; Selenium; Vita | 2003 |
Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cohort Stu | 2003 |
Preventing diabetic retinopathy through control of systemic factors.
Topics: Anticoagulants; Aspirin; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Female; G | 2003 |
Aspirin for cancer chemoprevention: still a headache?
Topics: Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; Cyclooxygenase Inhibitor | 2004 |
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Biomarkers; Blood Proteins; C-Reactive Protein; Coro | 2004 |
[Recurrent polychondritis: apropos of a case].
Topics: Aspirin; Autoimmune Diseases; Azathioprine; Biopsy; Carcinoma, Squamous Cell; Conjunctivitis; Cyclos | 2003 |
Preventive therapy in patients with insignificantly narrowed coronary arteries: evaluation of physician attitude and practice.
Topics: Adult; Aspirin; Attitude of Health Personnel; Coronary Disease; Coronary Vessels; Disease Progressio | 2004 |
Rupture of a giant coronary artery aneurysm due to Kawasaki disease.
Topics: Anticoagulants; Aspirin; Cardiac Tamponade; Child, Preschool; Combined Modality Therapy; Coronary An | 2004 |
Aspirin use in advanced uncontrolled glaucoma.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Glaucoma, Open- | 2004 |
Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular ultrasound.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Disease Progression; Female; Follow | 2004 |
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.
Topics: Acute Disease; Adult; Aged; Aspirin; Databases, Factual; Disease Progression; Disease-Free Survival; | 2005 |
Myeloid-related protein 8 expression on macrophages is a useful prognostic marker for renal dysfunction in children with MPGN type 1.
Topics: Adolescent; Aspirin; Biomarkers; Biopsy; Calgranulin A; Calgranulin B; Child; Creatinine; Cyclophosp | 2005 |
Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
Topics: Aspirin; Cardiovascular Diseases; Cholesterol; Chronic Disease; Disease Progression; Hemorrhage; Hum | 2005 |
Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage.
Topics: Administration, Oral; Aged; Aspirin; Brain Ischemia; Causality; Cerebral Arteries; Cerebral Hemorrha | 2005 |
Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin.
Topics: Animals; Aorta, Thoracic; Aspirin; Atherosclerosis; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dis | 2006 |
Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis.
Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Comorbidity; Disease Progression; Double-Blind Method | 2006 |
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immuno | 2006 |
The haematocrit and platelet target in polycythemia vera.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Female; Follow-Up Studi | 2007 |
A mechanistic interaction remains to be determined for elevated NTproBNP in heart failure patients receiving both an ACE inhibitor and aspirin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Disease Progression; Drug Antagonism; Drug Intera | 2007 |
The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis.
Topics: Animals; Aspartate Aminotransferases; Aspirin; Bilirubin; Disease Progression; Enoxaparin; Fibrinoly | 2007 |
Biomarkers identified to predict esophageal cancer susceptibility and aspirin found to lower cancer risk.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Biomarkers, Tum | 2007 |
Factors related to progression of middle cerebral artery stenosis determined using transcranial Doppler ultrasonograhy.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cerebral Angiography; Clopidogrel; Constriction, Pathologic; D | 2008 |
Benign long-term outcome of conservatively treated cervical aneurysms due to carotid dissection.
Topics: Adult; Aged; Aneurysm, Ruptured; Anticoagulants; Aortic Dissection; Aspirin; Carotid Artery, Interna | 2007 |
Case report on clopidogrel rash after coronary placement of a paclitaxol-coated stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Disease Progression; Drug H | 2007 |
Effect of statin drugs and aspirin on open-angle glaucoma progression.
Topics: Aspirin; Disease Progression; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Hydroxymethyl | 2007 |
Effect of statin drugs and aspirin on progression in open-angle glaucoma suspects using confocal scanning laser ophthalmoscopy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Child; Disease Progression; Drug Therapy, Combi | 2007 |
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
Topics: Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Disease Progression; Female; | 2008 |
Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo.
Topics: Animals; Aorta; Apolipoproteins E; Aspirin; Atherosclerosis; Blood Platelets; Carotid Arteries; Chol | 2008 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |
[Kawasaki disease].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Diagnosis, Differential; Disease Pro | 2007 |
Calcified occlusion of the coronary arteries in a young woman diagnosed with Kawasaki disease.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcinosis; Cardiomyopathies; Coronary | 2008 |
Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) September 2007.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Disease Progression; Exercise Test; Humans; Intermittent Cla | 2008 |
Epidemiological feasibility of cardiovascular primary prevention in general practice: a trial of vitamin E and aspirin. Collaborative group of the Primary Prevention Project.
Topics: Aged; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clinical Protocols; Contraindications; Dia | 1995 |
[Progression of livedo vasculitis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Dipyridamole; Disease Progression; Female; Huma | 1996 |
Effect of aspirin and sodium salicylate on cataract development in diabetic rats.
Topics: Animals; Aspirin; Cataract; Diabetes Mellitus, Experimental; Disease Progression; Drug Evaluation, P | 1998 |
Arachidonic acid-induced hind limb gangrene: a new experimental rat model of peripheral vascular disease.
Topics: Animals; Arachidonic Acid; Aspirin; Disease Models, Animal; Disease Progression; Drug Evaluation, Pr | 1999 |
Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability.
Topics: Adaptor Proteins, Signal Transducing; Aspirin; Base Pair Mismatch; Carrier Proteins; Cyclooxygenase | 1999 |
Pulse methylprednisolone therapy for impending cardiac tamponade in immunoglobulin-resistant Kawasaki disease.
Topics: Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac T | 1999 |
Selection of quantitative criteria for evaluating metastases of a highly metastatic salivary adenoid cystic carcinoma cell line to the lungs of nude mice.
Topics: Animals; Aspirin; Carcinoma, Adenoid Cystic; Disease Progression; Female; Image Processing, Computer | 1999 |
Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome.
Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoantibodi | 2000 |
Heparin versus aspirin in ischaemic stroke.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Disease Progression; Fibrinolytic Agents; Heparin, Low | 2000 |
[Platelet aggregation in patients with various forms of left ventricular hypertrophy and its changes at long-term follow-up and treatment].
Topics: Aspirin; Disease Progression; Echocardiography; Electrocardiography, Ambulatory; Follow-Up Studies; | 2000 |
Myeloproliferative syndromes. Current opinions from the European Hematology Association Working Group on Myeloproliferative Disorders.
Topics: Aspirin; Bone Marrow Examination; Clinical Trials as Topic; Clone Cells; Congresses as Topic; Diseas | 2001 |
Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Diseas | 2001 |
Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist.
Topics: Animals; Aspirin; Autocrine Communication; Cells, Cultured; Cinnamates; Cyclooxygenase Inhibitors; D | 2002 |